臨床腫瘍内科学入門

出版社： 永井書店
著者：
発行日： 2005-11-02
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 4815917329
電子書籍版： 2005-11-02 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

11,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

本書では、抗がん剤の基礎知識、分子標的療法剤の作用機序など全診療領域にわたるがん治療の基礎知識を解説するとともに、各診療科領域における最先端のがん治療を紹介することにより臨床腫瘍学を系統立てて、しかも奥深く学べるように各項目を設定した。

目次

  • 臨床腫瘍内科学入門

    ―目次―

    1．腫瘍内科学の進歩と変遷
    2．抗がん剤の作用機構
    3．がん治療における放射線療法の現状と今後の展望
    4．がん治療の最前線と今後の展望
    5．化学療法時の注意点
    6．がん患者のQOL向上のために
    7．がんの予防と早期発見
    8．化学療法の実際
    9．抗がん剤の適正使用ガイドライン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

II. 抗がん剤の作用機構

P.15 掲載の参考文献
1) Simon R, Kom EL : Selecting drug combinations based on total equivalent dose (dose intensity). J Natl Cancer Inst 82 : 1469-1476, 1990.
 
2) Simon R, Kom EL : Selecting combinations of chemotherapeutic drugs to maximize dose intensity. J biopharm stat 1 : 247-259, 199 L
 
3) Kom EL, Simon R : Using the tolerable-dose diagram in the design of phase 1 combination chemotherapy trials. J Clin Oncol 11 : 794-801, 1993.
 
4) Leventhal BH, Wittes RE : Combination Chemotherapy. Research Methods in Clinical Oncology (Leventhal BG, Wittes RE eds.). pp 129-149, New York, Raven Press, 1988.
 
5) Rowinsky EK, Gilbert MR, McGuire WP, et al : Sequences of taxol and cisplatin : a phase 1 and pharmacologic study. J Clin Oncol 9 : 1692-1703, 1991.
 
6) Oshita F, Noda K, Nishiwaki Y, et al : Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15 : 304-309, 1997.
PubMed
7) Fukuoka M, Niitani H, Suzuki A, et al : A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10 : 16-20, 1992.
 
8) Sasaki Y, Ohtsu A, Shimada Y, et al : Simultaneous administration of CPT-11 and fluorouracil : Alternation of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86 : 1096-1098, 1994.
 
9) Negoro S, Fukuoka M, Masuda N, et al : Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83 : 1164-1168, 1991.
PubMed
10) Masuda N, Fukuoka M, Takada M, et al : CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10 : 1775-1780, 1992.
PubMed
11) Masuda N, Fukuoka M, Kudoh S, et al : Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12 : 90-96 : 1994.
PubMed
12) Masuda N, Fukuoka M, Kudoh S, et al : Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12 : 1833-1841, 1994.
PubMed
13) Masuda N, Matsui K, Negoro S, et al : Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 : 3329-3334, 1998.
 
14) Masuda N, Negoro S, Kudoh S, et al : Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol 18 : 2996-3003, 2000.
PubMed
P.21 掲載の参考文献
1) Lotze MT : Chapter 9. Biologic Therapy with Interleukin-2 : Preclinical Studies. In Biologic Therapy of Cancer 2nd ed (De Vita VT Jr, Hellman S, Rosenberg SA, eds). pp207, Philadelphia, J B Lippincott, 1995.
 
2) Schwartzentruber DJ, et al : Chapter 10. Biologic Therapy with Interleukin-2 : Clinical Applications, In Biologic Therapy of Cancer 2nd ed (De Vita VT Jr, Hellman S, Rosenberg SA, eds). pp235, Philadelphia, J B Lippincott, 1995.
 
3) 藤原大美 : 腫瘍免疫学 第2版. 東京, 中外医学社, 2003.
 
4) 岸田綱太郎, 今西二郎 : インターフェロン. ライフサイエンス. 東京, 1998.
 
5) Yanai Y, et al : Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J Interferon Cytokine Res 21 : 835, 2001.
 
6) Takaoka A, et al : Integration of interferon-α/β signaling to p53 responses in tumor suppression and antiviral defence. Nature 424 : 516, 2003.
 
7) Sakon M, et al : Combined intraarterial 5-Fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94 : 435, 2002.
 
8) 癌免疫外科研究会 : エビデンスに立脚したBRM療法 (非特異的免疫賦活剤) の臨床適応基準 (発行者第25回癌免疫外科研究会山岸久一, 上田祐二). 2004.
 
9) Okamoto M, et al : Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a Streptococcal preparation. Cancer Res 64 : 5461, 2004.
 
10) 折田薫三, ほか : Danger signal, Toll-like receptorと癌免疫療法. Biotherapy 16 : 204, 2002.
Medical*Online
11) 折田薫三, ほか : 腫瘍の免疫逃避機構. Biotherapy 18 : 279, 2004.
Medical*Online
P.27 掲載の参考文献
1) Huggins C, Hodges CV : Studies on prostatic cancer : effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate . Cancer Res 1 : 293, 1941.
 
2) Beston GT : On the treatment of inoperable cases of carcinoma of the mamma : suggestions for a new method of treatment with iltustrative cases. Lancet 2 : 104-107 (part 1), 162-165 (part 2), 1984.
 
3) Jordan VC : The development of tamoxifen for breast cancer : a tribune to the late Arthur L. Wadpole. Breast Cancer Res Treat 11 : 197-209, 1988.
 
4) Hollenberg SM, Weinberger C, Ong ES, et al : Primary structure and expression of a functional human glucocorticoid receptor Cdna. Nature 318 : 635-641, 1985.
PubMed
5) Green S, Walter P, Kumar V, et al : Human oestrogen receptor Cdna : sequence, expression and homology to v-erb-A. Nature 320 : 134-139, 1986.
 
6) Mckenna NJ, Lanz RB and O7Malley BW : Nuclear receptor coregulators : cellular and molecular biology. Endocr Rev 20 : 321-344, 1999.
 
7) Pasqualini JR, Chetrite G, Blacker C, et al : Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81 : 1460-1464, 1996.
PubMed
8) Kaisary AV, Tyrrell CJ, Beacock C, et al : A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur Urol 28 : 215-222, 1995.
 
9) Tyrrell CJ, Kaisary AV, Iversen P, et al : A randomized comparison of 'Casodex'(TM) (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 : 447-456, 1998.
 
10) Carswell CI, Figgitt DP : Bicalutamide : in early-stage prostate cancer. Drugs 62 : 2471-2479, discussion : 2480-2481, 2002.
 
11) Labrie F, Dupont A, Belanger A, et al : New approach in the treatment of prostate cancer : complete instead of partial withdrawal of androgens. Prostate 4 : 579-594, 1983.
PubMed
12) Crawford ED, Eisenberger MA, McLeod DG, et al : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 : 419-424, 1989.
PubMed
13) Dijkman GA, Janknegt RA, De Reijke TM, et al : Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 158 : 160-163, 1997.
 
14) Akaza H, Yamaguchi A, Matsuda T, et al : Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer : interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34 : 20-28, 2004.
PubMed
15) Prostate Cancer Trialists-Collaborative Group : Maximum androgen blockade in advanced prostate cancer : an overview of the randomized trials. Lancet 355 : 1491-1498, 2000.
 
16) Kelly WK, Scher HI : Proastate specific antigen decline after antiandrogen withdrawal : the flutamide withdrawal syndrome. J Urol 149 : 607-609, 1993.
PubMed
17) Koj ima S, Suzuki H, Akakura K, et al : Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171 : 679-683, 2004.
 
18) Mongiat-Artus P, Teiilac P : Abarelix : the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 5 : 2171-2179, 2004.
 
19) Chen CD, et al : Molecular determinants of resistance to androgen therapy. Nat Med 10 : 33-39, 2004.
PubMed
20) Harada S, Keller ET, Fujimoto N, et al : Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 46 : 319-326, 2001.
PubMed
P.35 掲載の参考文献
1) 秋山伸一 : 新しい薬剤耐性のメカニズムとその克服, 癌と化学療法 30 : 1-8, 2003,
Medical*Online
2) 秋山伸一 : ABCトランスポーターと多剤耐性および疾病, 分子生物で病気を織るシリーズ5チャンネルとトランスポーターその働きと病気 (安田安信, 清野進編), pp510-589, 東京, メジカルビュー社, 1997.
 
3) Goldstein LJ. : Clinical reversal of drug resistance. Curr Probl Cancer 19 : 65-124, 1995.
 
4) htt9://nutrigene.4t.com/humanabc.htm 49 human ATP-binding Cassette transporters
 
5) Nooter K, Westerman AM, Flens MJ, et al : Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1 : 1301-1310, 1995.
PubMed
6) Norris MD, Bordow SB, Marshall GM, et al : Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334 : 231-238, 1996.
PubMed
7) Ohno N, Tani A, Chen ZS, et al : Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7 : 3120-3126, 2001.
PubMed
8) Kuss BJ, Deeley RG, Cole SP, et al : The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leuk Lymphoma 20 : 357-364, 1996.
PubMed
9) Doyle LA, Ross DD : Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 20 : 7340-7358, 2003.
 
10) Chresta CM, Masters JR, Hickman JA : Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional P53 and a high Bax : Bcl-2 ratio. Cancer Res 56 : 1834-1841, 1996.
 
11) Schmitt CA, Fridman JS, Yang M, et al : A senescence program controlled by p53 and p161NK4a contributes to the outcome of cancer therapy. Cell 109 : 335-346, 2002.
 
12) Wan X, Yokoyama Y, Shinohara A, et al : PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ 9 : 414-420, 2002.
PubMed
13) Yuan XJ, Whang YE : PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21 : 319-327, 2002.
PubMed
14) Zandi E, Chen Y, Karin M : Direct phosphorylation of lkappaB by IKKalpha and IKKbeta : discrimination between free and NF-kappaB-bound substrate. Science 281 : 1360-1363, 1998.
 
15) Ozes ON, Mayo LD, Gustin JA, et al : NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 : 82-85, 1999.
PubMed
16) le Coutre P, Tassi E, Varella-Garcia M, et al : Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95 : 1758-1766, 2000.
 
17) Mahon FX, Deininger MW, Schultheis B, et al : Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571 : diverse mechanisms of resistance. Blood 96 : 1070-1079, 2000.
 
18) Ricci C, Scappini B, Divoky V B, et al : Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 62 : 5995-5998, 2002.
 
19) Deininger MW, Goldman JM, Lydon N, et al : The tyrog. ine kinase inhibitor CGP57 148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90 : 3691-3698, 1997.
 
20) Gorre ME, Mohammed M, Ellwood K, et al : Clinical resistance to STI-571cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 : 876-802, 2001.
PubMed
21) Schindler T, Bornmann W, Pe11icena P, et al : Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 : 1938-1942, 2000.
 
22) Lu Y, Zi X, Pollak M : Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108 : 334-341, 2004.
 
23) Price-Schiavi SA, Jepson S, Li P, et al : Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99 : 783-791, 2002.
PubMed
24) Ren XQ, Furukawa T, Aoki S, et al : Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J Biol Chem 276 : 23197-23206, 2001.
 
25) Ren XQ, Furukawa T, Aoki S, et al : A positively charged amino acid proximal to the C-terminus of TM 17 of MRPI is indispensable for GSH-dependent binding of substrates and for transport of LTC4. Biochemistry 3 : 14132-14140, 2002.
 
26) Plumb JA, Strathdee G, Sludden J, et al : Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60 : 6039-6044, 2000.
PubMed
27) Shah NP, Tran C, Lee FY, et al : Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 : 399-401, 2004.
PubMed
28) Kerbel RS, Kamen BA : The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 : 423-436, 2004.
PubMed

III. がん治療における放射線療法の現状と今後の展望 単独治療あるいは内科的外科的治療との併用について

P.44 掲載の参考文献
1) Bernier J, Bentzen SM : Altered fractionation and combined radio-chemotherapy approaches : pioneering new opportunities in head and neck oncology. Eur J Cancer 39 (5) : 560-71, 2003
PubMed
2) Furuse K, et al : Phase III study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 13 : 869, 199
 
3) Ohtsu A, et al : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17 : 2915-2921, 1999
 
4) Warde P, Payne D. : Does thoracic irradiation improve survival and local control in limited stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992, 10 : 890-5
 
5) Murray N, Coy P, Pater JL, et al. : Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. JChn Oncol 1993 : 11 : 336-44
 
6) Auperin A, Arriagada R, Pinon JP, et al. : Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial lrradiation Overview Collaborative Group. N Engl J Med 1999 ; 341 : 476-84
 
7) Pollack A, Zagars GK, Starkschall G, et al. : Prostate cancer radiation dose response : results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (5) : 1097-105, 2002
 
8) Miller TP, Dahberg S, Cassady J R, et al. : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma N Engl J Med ; 339 : 21-26, 1998
PubMed

IV. がん治療の最前線と今後の展望

P.50 掲載の参考文献
1) Goodman LS, Wintrobe MM, Dameshek W, et al : Use of methyl-bis (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 132 : 126-132, 1946.
 
2) Druker BJ, Tamura S, Buchdunger E, et al : Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 : 561-566, 1996.
PubMed
3) 河合泰一, 上田孝典, 陣内逸郎, ほか : STI571 (グリベック) のPhiladelphiaの染色体陽性慢性期慢性骨髄性白血病患者に対する第二相試験. 臨床血液 43 : 103, 2002.
 
4) O'Brien SG, Guilhot F, Larson RA, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 : 994-1004, 2003.
PubMed
5) Hurwitz H, Fehrenbacher L, Novomy W, et al : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 : 2335-2342, 2004.
 
6) Fukuoka M, Yano S, Giaccone G, et al : Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 : 2237-2246, 2003.
PubMed
7) Kris MG, Natale RB, Herbst RS, et al : Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell阯ng cancer : a randomized trial. JAMA 290 : 2149-2158, 2003.
 
8) Kohler G, Milstein C : Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 : 495-497, 1975.
PubMed
9) Morrison SL, Johnson MJ, Herzenberg LA, et al : Chimeric human antibody molecules : mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81 : 6851-6855, 1984.
PubMed
10) Verhoeyen M, Milstein C, Winter G : Reshaping human antibodies : grafting an antilysozyme activity. Science 239 : 1534-1536, 1988.
PubMed
11) Druker BJ, Talpaz M, Resta DJ, et al : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 : 1031-1037, 2001.
PubMed
12) Lynch TJ, Bell DW, Sordella R, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004.
PubMed
13) Paez JG, Janne PA, Lee JC, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004.
PubMed
14) Shah NP, Sawyers CL : Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22 : 7389-7395, 2003.
PubMed
15) Yoshida S, Fukumoto S, Kawaguchi H, et al : Ganglioside G (D2) in small cell lung cancer cell lines : enhancement of cell proliferation and mediation of apoptosis. Cancer Res 61 : 4244-4252, 2001.
PubMed
16) Ishida T, Utsunomiya A, Iida S, et al : Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma : its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9 : 3625-3634, 2003.
PubMed
17) Chabner BA, Boral AL, Multani P : Translational research : walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture. Cancer Res 58 : 4211-4216, 1998.
 
18) 上田龍三, 佐藤滋樹 : 抗悪性腫瘍薬の適応とリスクベネフィット抗悪性腫瘍薬開発に必須のトランスレーショナルリサーチ. 日本医師会雑誌 130 : 1065-1069, 2003.
 
19) Demetri GD, von Mehren M, Blanke CD, et al : Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 : 472-480, 2002.
PubMed
20) Vogel CL, Cobleigh MA, Tripathy D, et al : Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 : 719-726, 2002.
PubMed
P.54 掲載の参考文献
1) Cardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 ('Iressa'), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000 ; 6 : 2053-2063.
 
2) Sirotnak FM, Zakowski MF, Miller VA, et al. Effi cacy of cytotoxic agents against human tumor xenografts is markedly enhanced bycoadministration of ZD 1839 ('Iressa') an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000 ; 6 : 4885-4892.
 
3) Kris M, Herbst R, Rischin D, et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZDI839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor. (EGFR). Lung Cancer 2000 ; 29 (suppl) : 72. Abstract 223
 
4) Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 2001 ; 20 : 324a. Abstract 1292
 
5) Ranson M, Hammond L, Ferry D, et al. ZD1839 ('Iressa'), a selective oral EGFR-TK1 (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumors : results of a Phase I trial. J Clin Oncol 2002 ; 30 : 2240-2250.
 
6) Joan Albanell, Federico Rojo, Steve Averbuch, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients : histopathologic and molecular consequences of receptor inhibition. Journal of Clin Oncol 2002 ; 20 : 110-124
 
7) Fukuoka M, Yano S, Giaccone G, et al. Final results from a Phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002 ; 21 : 298a. Abstract 1188
 
8) Kris MG, Natale RB, Herbst RS, et al. A Phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL-2). Proc Am Soc Clin Oncol 2002 ; 21 : 292a. Abstract 1166.
 
9) Giaccone G, on behalf of the INTACT 1 investigators. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). 27th ESMO Congress, October 18-22, 2002, Nice, France. Abstract 4
 
10) Johnson DH, on behalf of all INTACT 2 investigators. X1839 ('Iressa') in combination with paclitaxel and CBDCA in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) : results from a phase III trial (INTACT 2). 27th ESMO Congress, October 18-22, 2002, Nice, France. Abstract 468
 
11) Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003 ; 361 : 137-139.
PubMed
12) Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science ; 304 : 1497-1500. 2004
PubMed
13) Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. ; 350 : 2129-2139. 2004
PubMed
14) Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung canccrs from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci ; 101 : 13306-13311. 2004
PubMed
15) Doi T, Koizumi W, Siena S et al. Effucacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer (abstruct) J CO 22 (proceeding) : 258, 2003
 
16) Rojo F, Tabernero J, Van Cutsem E, et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839) (abstruct). JCO 22 (proceeding) : 192, 2003
 
17) O. Dorligschaw T, Kegel K, Jordan A, et al. ZD1839 (Iressa) -based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC) (abstruct 1494) JCO 22 (proceeding) : 372 ; 2003
 
18) G. A. Fisher T, Kuo C. D, Cho J, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. (abstruct3514) JCO 22 (proceeding) : 14S ; 2004
 
19) C. Van Groeningen, D. Richel, G. Giaccone et aLGefitinib phase II study in second-line treatment of advanced esophageal cancer. (abstruct 4022) JCO 22 (proceeding) : 14S ; 2004
 
P.59 掲載の参考文献
1) Druker BJ, Talpaz M, Resta DJ, et al : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 : 1031-1037, 2001.
PubMed
2) Buchdunger E, Zimmermann J, Mett H, et al : Inhibition of the Ab protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56 : 100-104, 1996.
 
3) Druker BJ, Tamura S, Buchdunger E, et al : Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 : 561-566, 1996.
PubMed
4) Schindler T, Bornmann W, Pellicena P, et al : Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 : 1938-1942, 2000.
PubMed
5) O'Brien SG, Guilhot F, Larson RA, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 : 994-1004, 2003.
PubMed
6) Hughes TP, Kaeda J, Branfbrd S, et al : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 : 1423-1432, 2003.
PubMed
7) Talpaz M, Silver RT, Druker BJ, et al : Imatinib induces durable hematologic and cytogenetic responses in patients with accclerated phase chronic myeloid leukemia : results of a phase 2 study. Blood 99 : 1928-1937, 2002.
PubMed
8) Sawyers CL, Hochhaus A, Feldman E, et al : Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis : results of a phase II study. Blood 99 : 3530-3539, 2002.
PubMed
9) Hochhaus A, Kreil S, Corbin AS, et al : Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 : 2190-2196.
PubMed
10) Kantarjian H, Talpaz M, O'Brien S, et al : High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 : 2873-2878, 2004.
PubMed
11) Shah NP, Nicoll JM, Nagar B, et al : Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 : 117-125, 2002.
 
12) Branford S, Rudzki Z, Walsh S, et al : Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 : 276-283, 2003.
 
13) Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al : Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 : 1052-1056, 2001.
 
14) Verweij J, Casali PG, Zalcberg J, et al : Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial. Lancet 364 : 1127-1134, 2004.
PubMed
15) Cools J, DeAngelo DJ, Gotlib J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIPIL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 : 1201-1214, 2003.
 
16) Pardanani A, Tefferi A : Imatinib targets other than bcr/abl and their clinicai relevance in myeloid disorders. Blood 104 : 1931-1939, 2004.
 
P.63 掲載の参考文献
1) Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein famesyltransferase : A strategic target for anticancer therapeutic development. J Clin Oncol 1999 ; 17 : 3631-52.
 
2) Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 2003 ; 17 : 1482-98.
PubMed
P.66 掲載の参考文献
1) Adams J : The proteasome : a suitable antineoplastic target. Nat Rev Cancer 4 : 349-360, 2004.
PubMed
2) Park DJ, Lenz HJ : ; The role of proteasome inhibitors in solid tumors. Ann Med 36 : 296-303, 2004.
PubMed
3) Richardson PG, Hideshima T, Mitsiades C, et al : Proteasome inhibition in hematologic malignancies. Ann Med 36 : 304-314, 2004.
PubMed
P.70 掲載の参考文献
1) Reff ME, et al : Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 84 : 435-445, 1994.
 
2) Maloney DG, et al : Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 : 2457-2466, 1994.
PubMed
3) McLaughlin P, et al : Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients responded to a four-dose treatment program. J Clin Oncol 16 : 2825-2833, 1998.
 
4) Tobinai K, et al : Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cemymphoma. Ann Oncol 9 : 527-534, 1998.
PubMed
5) Igarashi T, et al : Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab : Japanese phase II study. Ann Oncol 13 : 928-943, 2002.
PubMed
6) Czuczman MS, et al : Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 : 268-276, 1999.
PubMed
7) Coiffier B, et al : Rituximab (anti-CD20 monoclonal antibody) for treatment of patients with relapsing or refractory aggressive lymphoma : A multicenter phase II study. Blood 92 : 1927-1932, 1998.
 
8) Tobinai K, et al : Japanese muticenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15 : 821-830, 2004.
PubMed
9) Coiffier B, et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 : 235-242, 2002.
PubMed
10) Knox S, Goris M, Trisler K, et al : Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 : 457-470, 1996.
PubMed
11) Witzig TE, Whiter CA, Wiseman GA, et al : Phase IAI trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 : 3793-3803, 1999.
PubMed
12) Witzig TE, Gordon LI, Cabanillas F, et al : Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 : 2453-2463, 2002.
 
P.74 掲載の参考文献
1) Hanahan D, Folkman J : Patterns and emerging mechanis. ms of the angiogenic switch during tumorigenesis. Cell 86 : 353-364, 1996.
 
2) Baldwin ME, Stacker SA, Achen MG : Molecular control of lymphangiogenesis. Bioessays 24 : 1030-1040, 2002.
PubMed
3) 小野眞弓, 桑野信彦二抗血管新生と療法の現状. 血管新生研究の新しい展開 (佐藤靖史編). 医学のあゆみ (別冊) : 817-823, 2002.
 
4) 三島麻衣, 丸山祐一郎, 桑野隆史, ほか : 消化器がんの分子標的治療 : 59-72, 2004.
 
5) 藤井輝彦, 山名秀明, 桑野信彦 : 血管新生阻害薬. 胃がんの治療 19 : 980-987, 2004.
 
6) Leek RD, Lewis CE, Whitehouse R, et al : Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56 : 4625-4629, 1996.
PubMed
7) Toi M, Ueno T, Matsumoto H, et al : Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 5 : 1131-1137, 1999.
PubMed
8) Kuwano M, Basaki Y, Kuwano T, et al : The critical role of Inflammatory cell infiltration in tumor angiogenesis-a target for antitumor drug development? Progress in Angiogenesis Research, N. Y. in press, Nova Science Publishers, Inc., 2005.
 
9) Coussens LM, Werb Z : Inflammation and cancer. Nature 420 : 860-867, 2002.
PubMed
10) Pollard JW : Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4 : 71-78, 2004.
PubMed
11) Kuwano T, Nakao S, Yamamoto H, et al : Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18 : 300-310, 2004.
PubMed
12) 桑野信彦, 藤井輝彦, 小野眞弓, ほか : 分子標的治療の現状と将来への展望. 日本臨牀 : 1211-1215, 2004.
 
13) 桑野信彦, 小野眞弓, 内海健, ほか : がんの分子標的治療法. Medico : 125-130, 2002.
 
14) Hirata A, Ogawa S, Kometani T, et al : ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62 : 2554-2560, 2002.
PubMed
15) Hirata A, Uehara H, Izumi K, et al : Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Science 95 : 1-5, 2004.
PubMed
16) Marm6 D : The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin 129 : 607-620, 2003.
 
P.77 掲載の参考文献
1) 富田章裕, 直江知樹 : 分子標的としてのヒストン脱アセチル化酵素, 実験医学 : 22 (増刊), 2004.
 
2) Yoshida M, Matsuyama A, Komatsu Y, : From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10 : 2351-2358, 2003.
 
3) Somech R, Izraeli S, J Simon A : Histone deacetylase inhibitors-a new tool to treat cancer. Cancer Treat Rev 30 : 461-472, 2004.
PubMed
4) Kelly WK, O℃onnor OA, Marks PA. : Histone deacetylase inhibitors : from target to clinical trials. Expert Opin lnvestig Drugs 11 : 1695-1713, 2002.
 
5) Villar-Garea A, Esteller M : Histone deacetylase inhibitors : understanding a new wave of anticancer agents. Int J Cancer 112 : 171-178, 2004.
PubMed
P.83 掲載の参考文献
1) Thun MJ : Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 : 1593-1596, 1991.
PubMed
2) Schreinemachers DM, Everson RB : Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5 : 138-146, 1994.
 
3) Eberhart CE, et al : Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 : 1183-1188, 1994.
PubMed
4) Hida T, Yatabe Y, Achiwa H, et al : Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58 : 3761-3764, 1998.
PubMed
5) Oshima M, Dinchuk JE, Kargman SL, et al : Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87 : 803-809, 1996.
 
6) Steinbach G, Lynch PM, Phillips RKS, et al : The effect of celecoxib, acyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 : 1946-1952, 2000.
 
7) Hida T, Kozaki K, Muramatsu H, et al : Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6 : 2006-2011, 2000.
PubMed
8) Tsujii M, Dubois RN : Alterlations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 : 493-501, 1995.
PubMed
9) Kozaki K, Miyaishi O, Tsukamoto T, et al : Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent rymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res 60 : 2535-2540, 2000.
PubMed
10) Tsujii M, Kawano S, Dubois RN : Cyclooxygenase 2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94 : 3336-3340, 1997.
PubMed
11) Hida T, Kozaki K, Ito H, et al : Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8 : 2443-2447, 2002.
PubMed
12) Tsujii M, Kawano S, Tsuji S, et al : Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 : 705-716, 1998.
PubMed
13) Nataraj C, Thomas DW, Tilley SL, et al : Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse. J Clin Invest 108 : 1229-1235, 2001.
PubMed
14) Yang Li, Yamagata N, Yadav R, et al : Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111 : 727-735, 2003.
PubMed
15) DeLong P, Tanaka T, Kruklitis R, et al : Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 63 : 7845-7852, 2003.
PubMed
16) Achiwa H, Yatabe Y, Hida T, et al : Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5 : 1001-1005, 1999.
PubMed
17) Emery P, Zeidler H, Kvien TK, et al : Celecoxib versus diclofenac in long-term management of rheumatoid arthritis : randomized double-blind comparison. Lancet 354 : 2106-2111, 1999.
PubMed
18) Hida T, Leyton J, Makheja AN, et al : Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 18 : 775-782, 1998.
PubMed
19) Kozaki K, Koshikawa K, Tatematsu Y, et al : Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 20 : 4228-4234, 2001.
PubMed
20) Thun MJ, Henley SJ, Patrono C : Nonsteroidal anti-inflammatory drugs as anticancer agents : mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 : 252-266, 2002.
PubMed
21) Altorki NK, Keresztes RS, Port JL, et al : Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 : 2645-2650, 2003.
PubMed
22) Ferrandina G, Lauriola L, Distefano MG, et al : Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20 : 973-981, 2002.
PubMed
23) Ferrandina G, Lauriola L, Zannoni GF, et al : Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13 : 1205-1211, 2002.
PubMed
24) Patel VA, Dunn MJ, Sorokin A : Regulation of MDR-1 (P-glycoprotein) by Cyclooxygenase-2. J Biol Chem 277 : 38915-38920, 2002.
PubMed
25) Subbaramaiah K, Mamlo TP, Dixon DA, et al : Regulation of cyclooxygenase-2 mRNA stability by taxanes. J Biol Chem 278 : 37637-37647, 2003.
 
26) Buchanan FG, Wang D, Bargiacchi F, et al : Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 : 35451-35457, 2003.
PubMed
27) Torrance CJ, Jackson PE, Montgomery E, et al : Combinatorial chemoprevention of intestinal neoplasia. Nature Med 6 : 1024-1028, 2000.
PubMed
28) Totzke G, Schulze-Osthoff K, Janicke RU : Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 22 : 8021-8030, 2003.
PubMed
29) Tegeder I, Pfeilschifter J, Geisslinger G : Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 : 2057-2072, 2001.
PubMed
30) Sengupta S, Jang BC, Wu MT, et al : The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 278 : 25227-25233, 2003.
PubMed
31) Erkinheimo TL, Lassus H, Sivula A, et al : Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 63 : 7591-7594, 2003.
PubMed
32) Harvey R, Depner UB, Wassle H, et al : GlyR α3 : An essential target forspinal PGE2-mediated inflammatory pain sensitization. Science 304 : 884-887, 2004.
 
33) Syriatowicz JP, Hu D, Walker JS, et al : Hyperalgesia due to nerve injury : role of prostaglandins. Neuroscience 94 : 587-594, 1999.
PubMed
34) Ma W, Eisenach JC : Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 121 : 691-704, 2003.
PubMed
P.85 掲載の参考文献
1) Meijer L, Raymond E : Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36 : 417-425, 2003.
PubMed
2) Senderowicz AM : Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2 (4 Suppl 1) : S84-95, 2003.
 
3) Dai Y, Grant S : Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr Oncol Rep 6 : 123-30, 2004.
PubMed
P.88 掲載の参考文献
1) Visse R, Nagase H : Matrix metalloproteinases and tissue inhibitor of metalloproteinases. Structure, function, and biochemistry. Circ Res 92 : 827-839, 2003.
PubMed
2) Coussens LM, Fingleton B, Matrisian LM : matrix metalloproteinase inhibitors and cancer : Trials and tribulations. Science 295 : 2387-2392, 2002.
PubMed
3) Ramnath NJ, Creaven PJ : Matrix metalloproteinase inhibitors. Curr Oncol Rep 6 : 96-102, 2004.
 
P.97 掲載の参考文献
1) 日本造血細胞移植学会平成16年度全国調査報告書 2004年12月 p51
 
2) 日本造血細胞移植学会平成16年度全国調査報告書 2004年12月 p61
 
3) Rowley SD, et al. : Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 97 ; 2541-2548, 2001.
PubMed
4) Kodera Y, et al. : Severe adverse events or allogeneic peripheral blood stem cell donors ; results of nation-wide 2,784 prospectively registered case survey and of its comparison to bone marrow donors in Japan. Bone Marrow Transplant 35 (Suppl 2) S3, 2005.
 
5) Culter C, et al. : Acute and chronic graft-versus-host disease after peripheral-blood stem cell and bone marrow transplantation : A meta-analysis. J Clin Oncol 19 : 3685-3691, 2001.
 
6) Bensinger WI, et al : Transplantation of bone marrow as compared with peripheral blood stem cells from HLA-identical relatives in patients with hematologic malignancies. N Engl J Med 344 ; 175-181, 2001.
PubMed
7) Oebler VG, et al. : Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 11 ; 85-92, 2005.
 
8) Schmitz N, et al. : Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia : 3-year results from the EBMT randomized trial Hematologica 90 ; 643-648, 2005.
 
9) Couban S, et al. : Long-term follow-up of the Canadian Blood and Marrow Transplant Group (CBMTG) randomized study comparing bone marrow and peripheral blood in recipients of matched sibling allografts. Bone Marrow Transplant 35 (Suppl 2) ; S86, 2005.
 
10) Laughlin MJ, et al. : Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 ; 2265-2275, 2004.
 
11) Rocha V, et al. : Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 ; 2276-2285, 2004.
 
12) Takahashi S, et al. : Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104 ; 3. 813-3820, 2004.
 
13) Tamaki S, et al. : Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant 28 : 375-380, 2001.
PubMed
14) Ichinohe T, et al. : Feasibility of HLA-haploidentical hematopoietic stem-cell transplantation between non-inherited maternal antigen (NIMA) -mismatched family members linked with long-term reto-maternal microchimerism, Blood 104 ; 3821-3828, 2004.
 
15) Ruggeri L, et al. : Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 : 2097-2100, 2002.
 
16) Giralt S, et al. : Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy : harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 ; 4531-4536, 1997.
PubMed
17) Childs R, et al. : Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation : fill donor T-cell chimerism precedes alloimmune response. Blood 94 ; 3234-3241, 1999.
 
18) Slavin S, et al. : Nonmyeloablative stem cell transplantation and cell therapy as an altemative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 ; 756-763, 1998.
 
19) Carella AM. et al. : Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 18 ; 3918-3924, 2000.
PubMed
20) Storb R, et al. : Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 ; 3408-3054, 1997.
 
21) Maris MB, et al. : HLA-matched unrelated donor hematopoietic cell transplantation after nonmyetoablative conditioning for patients with hematologic malignancies. Blood 102 ; 2021-2023, 2003.
PubMed
P.103 掲載の参考文献
1) Sullivan KM, Weiden PL, Storb R, et al : Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320 : 828, 1989.
PubMed
2) Horowitz MM, Gale RP, Sondel PM, et al : Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 : 555, 1990.
PubMed
3) Cullis JO, Jiang YZ, Schwarer AP, et al : Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79 : 1379-1381, 1992.
PubMed
4) Eibl B, Schwaighofer H, Nachbaur D, et al : Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88 : 1501, 1996.
 
5) Ueno NT, Rondon G, Mirza N Q, et al : Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16 : 986, 1998.
PubMed
6) Porter DL, Connors JM, Van Deerlin VM, et al : Graft-versus-tumor induction with donor leucocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 17 : 1234, 1999.
PubMed
7) Sykes M : Mixed chimerism in the treatment of malignant and non-malignat diseases : studies in mice and their clinical applications. Non-myeloablative stem cell transplantation (NST) (ed by Giralt S, Slavin S), pp25-36, United Kingdom, Darwin Scientific Publishing.
 
8) Sandmaier BM : Post-transplant immunosuppressionミcanine models and clinical application. Non-myeloablative stem cell transplantation (NST) (ed by Giralt S, Slavin S), pp37-44, United Kingdom, Darwin Scientific Publishing.
 
9) Khouri IF, Keating M, Korbling M, et al : Transplant-lite : induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology 16 : 2817-2824, 1998.
PubMed
10) Giralt S, Estey E, Albitar M, et al : Melphalan and purine analogミcontaining preparative regimens : reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 : 631, 2001.
 
11) Slavin S, Nagler A, Naparstek E, et al : Nonmyeloablative stem cell transplantation and cell therapy as an altemative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 : 756, 1998.
 
12) Childs R, Clave E, Contentin N, et al : Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation : full donor T-cell chimerism precedes alloimmune responses. Blood 94 : 3234, 1999.
PubMed
13) McSweeney P, Niederwieser D, Shizuru JA, et al : Hematopoietic cell transplantation in older patients with hematologic malignancies : replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 : 3390-3400, 2001.
PubMed
14) Childs R, Chemoff A, Contentin N, et al : Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med 343 : 750, 2000.
PubMed
15) Childs R : Update NCI experienceミrenal and others. International Workshop on Non-myeloablative Stem Cell Transplantation. 2002.
 
16) Childs RW, et al : Non-myeloablative allogeneic stem cell transplantation for metastatic melanoma : Nondurable chemotherapy responses without clinically meaningful graft-vs-tumor effects. Blood 100 (suppl 1) : 429a, 2002.
 
17) Rini BI, Zimmeman T, Stadler WM, et al : Allogeneic stem-cell transplantation of renal cell Cancer after nonmyeloablative chemotherapy : Feasibility, engraftment, and clinical results. J Clin Oncol 20 : 2017-2024, 2002.
 
18) Bregni M, Dodero A, Peccatori J, et al : Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99 : 4234-4236, 2002.
PubMed
19) Pedrazzoli P, Da Prada GA, Giorgiani G, et al : Allogeneic Blood Stem Cell Transplantation after a Reduced-lntensity, Preparative Regimen A Pilot Study in Patients with Refractory Malignancies. Cancer 94 : 2409-2415, 2002.
PubMed
20) Ueno NT, Cheng YC, Rondon G, et al : Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem-cell transplantation for metastatic solid tumors. Blood 102 : 3829-3836, 2003.
PubMed
21) Hentschke P, Barkholt L, Uzunel M, et al : Low-intensity conditioning and hematopoietic stem cell transp! antation in patients with rcnal and colon carcinoma. Bone Marrow Transplant 31 : 253-261, 2003.
 
22) Blaise D, et al : Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103 : 435-441, 2004.
PubMed
23) Kanda Y, Izutsu K, Hirai H, et al : Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia l 8 : 1013-1019, 2004.
 
24) Mena O, Igarashi T, Srinivasan R, et al : Immunologic mechanisms involved in the graft-vs-tumor (GVT) effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation (NST). Blood abstr : 3555, 2001.
 
25) Kaufman HL, Di Vito J. Jr, Horig H : Immunotherapy for pancreatic cancer : current concepts. Hematol Oncol Clin North Am 16 : 159-197, 2002.
PubMed
P.116 掲載の参考文献
1) Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al : Gene therapy of human severe combined immunodeficiency (SCID) -X1 disease. Science 288 : 669-672, 2000.
PubMed
2) Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al : LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 : 415-419, 2003.
PubMed
3) Wu X, Li Y, Crise B, et al : Transcription start regions in the human genome are favored targets for MLV integration. Science 300 : 1749-1751, 2003.
 
4) Asano T, Hanazono Y, Ueda Y, et al : Highly efficient gene transfer into primate embryonic stem cells with a simian lentivirus vector. Mol Ther 6 : 162-168, 2002.
PubMed
5) Schnepp BC, Clark KR, Klemanski DL, et al : Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 77 : 3495-3504, 2003.
PubMed
6) Chao H, Liu Y, Rabinowitz J, et al : Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2 : 619-623, 2000.
PubMed
7) Gao GP, Alvira MR, Wang L, et al : Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99 : 11854-11859, 2002.
PubMed
8) Roth JA, Grammer SF, Swisher SG, et al : Gene therapy approaches for the management of non-small cell lung cancer. Semin Oncol 28 (4 Suppl 14) : 50-56, 2001.
 
9) Oohira G, Yamada S, Ochiai T, et al : Growth suppression of esophageal squamous cell carcinoma induced by heavy carbon-ion beams combined with p53 gene transfer. Int J Oncol 25 : 563-569, 2004.
PubMed
10) Edelman J, Edelman J, Nemunaitis J : Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr Opin Mol Ther 5 : 611-617, 2003.
PubMed
11) Touraine RL, Vahanian N, Ramsey WJ, et al : Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 9 : 2385-2391, 1998.
PubMed
12) Rainov NG : A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther l 1 : 2389-2401, 2000.
 
13) Trask TW, Trask RP, Aguilar-Cordova E, et al : Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1 : 195-203, 2000.
PubMed
14) Khuri FR, Nemunaitis J, Ganly I, et al : A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6 : 879-885, 2000.
PubMed
15) Simons JW, Mikhak B, Chang JF, et al : Induction of immunity to prostate cancer antigens : results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex vivo gene transfer. Cancer Res 59 : 5160-5168, 1999.
PubMed
16) Chinnasamy N, Treisman JS, Oaks MK, et al : Ex vivo generation of genetically modified dendritic cells for immunotherapy : implications of lymphocyte contamination. Gene Ther 12 : 259-271, 2005.
PubMed
17) Hasumi Y, Mizukami H, Urabe M, et al : Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 62 : 2019-2023, 2002.
PubMed
18) Kohno T, Mizukami H, Suzuki M, et al : Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63 : 5091-5094, 2003.
PubMed
19) Abonour R, Williams DA, Einhom L, et al : Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6 : 652-658, 2001.
 
20) Bonini C, Ferrari G, Verzeletti S, et al : HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 : 1719-1724, 1997.
PubMed
21) Verzeletti S, Bonini C, Marktel S, et al : Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia : clinical follow-up and improved new vectors. Hum Gene Ther 9 : 2243-2251, 1998.
PubMed
22) Kodaira H, Kume A, Ogasawara Y, et al : Fas and mutant estrogen receptor chimeric gene : anovel suicide vector for tamoxifen-inducible apoptosis. Jpn J Cancer Res 89 : 741-747, 1998.
 
23) Parker LL, Do MT, Westwood JA, et al : Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 11 : 2377-2387, 2000.
PubMed
24) Okada T, Caplen NJ, Ramsey WJ, et al : In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo. J Gene Med 6 : 288-299, 2004.
PubMed
25) Kanazawa T, Mizukami H, Okada T, et al : Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 10 : 51-58, 2003.
PubMed
26) Kanazawa T, Mizukami H, Nishino H, et al : Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells. Int J Oncol 25 : 729-735, 2004.
PubMed
P.121 掲載の参考文献
1) Couzin J : Breakthrough of the year. Small RNAs make big splash. Science 298 : 2296-2297, 2002.
PubMed
2) Zamecnik PC, Stephenson ML : Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75 : 280-284, 1978.
PubMed
3) Marwick C. : First "antisense" drug will treat CMV retinitis. JAMA 280 : 871, 1998.
PubMed
4) Cech TR, Zaug AJ, Grabowski PJ : In vitro splicing of the ribosomal RNA precursor of Tetrahymena : involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 27 : 487-496, 198 L
 
5) Fire A, Xu S, Montgomery MK, et al : Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 : 806-811, 1998.
PubMed
6) Elbashir SM, Harborth J, Lendeckel W, et al : Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 : 494-498, 2001.
PubMed
7) Brummelkamp TR, Bemards R, Agami R : Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2 : 243-247, 2002.
 
8) Check E : Atragic setback. Nature 420 : 116-118, 2002.
PubMed
9) Song E, Lee S K, Wang J, et al : RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med 9 : 347-351, 2003.
 
10) Nogawa M, Yuasa T, Kimura S, et al : Intravesical administration of small interfering RNA targeting PLK-l successfully prevents the growth of bladder cancer. J Clin Invest 115 : 978-85, 2005.
 
P.129 掲載の参考文献
1) Watters J W, H L McLeod, Canccr pharmacogcnomics : current and future applications. Biochim Biophys Acta 1603 : 99-111, 2003.
 
2) Quackenbush J : Microarray data normalization and transformation. Nat Genet 32 : 496-501, 2002.
PubMed
3) Simon R, A P Lam : http://www.sciencedirect.com/science?_ob=RedirectURL&_method=extemObjLink&_locator=ur1&_cdi=4886&_plusSign=%2B&_targetURL=http%253A%252F%252Flinus.nci.nih.gov%252FBRB-ArrayTools.html. (accessed Jun 1, 2004).
 
4) Eisen M B, et al : Cluster analysis and display of genome-wide expression pattems. Proc Natl Acad Sci U S A 95 : 14863-14868, 1998.
 
5) Chung C K, et al : Fluoride release and cariostatic ability of a compomer and a resin-modified glass ionomer cement used for orthodontic bonding. J Dent 26 : 533-538, 1998.
 
6) Simon R, et al : Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 : 14-18, 2003.
PubMed
7) van't Veer LJ, Dai H, van de Vijver MJ, et al : Gene expression profiling predicts clinical outcome of breast cancer. Nature 425 : 530-536, 2002
 
8) Ein-Dor L, Kela I, Getz G, et al : Outcome signature genes in breast cancer. Is there a unique set? Bioinformatics 15 ; 21 (2) : 171-178, 20056 Jan
 
9) Society M G E D S-M : http://www.mged.org/.
 
10) http://www.mext.go.jp/a_menu/shinkou/seimei/genomeshishin.
 
P.136 掲載の参考文献
1) Weinshilboum RM, Sladek SL : Mercaptopurine pharmacogenetics : monogenic inheritance of erythrocyte thiopurine methyltrang. ferase activity. Am J Hum Genet 1980, 32, 651-62
 
2) Krynetski EY, Tai HL, Yates CR, et al. : Genetic polymorphism of thiopurine S-methyltransferase : clinical importance and molecular mechanisms. Pharmacogenetics 1996, 6, 279-90
 
3) Tai HL, Fessing MY, Bonten EJ, et al. : Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells : mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999, 9, 641-50
PubMed
4) Tai HL, Krynetski EY, Schuetz EG, et al. : Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2) : mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 1997, 94, 6444-9
 
5) Collie-Duguid ES, Pritchard SC, Powrie RH, et al. : The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999, 9, 37-42
 
6) McLeod HL, Pritchard SC, Githang'a J, et al. : Ethnic differences in thiopurine methyltransferase pharmacogenetics : evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999, 9, 773-6
PubMed
7) Ottemess D, Szumlanski C, Lennard L, et al. : Human thiopurine methyltransferase phamacogenetics : gene sequence polymorphisms. Clin Pharmacol Ther 1997, 62, 60-73
 
8) Yates CR, Krynetski EY, Loennechen T, et al. : Molecular diagnosis of thiopurine S-methyltransferase deficiency : genetic basis for azathioprine and mercaptopurine intolerance. Ann Intem Med 1997, 126, 608-14
 
9) Hiratsuka M, Inoue T, Omori F, et al. : Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res 2000, 448, 91-5
 
10) Yan L, Zhang S, Eiff B, et al. : Thiopurine methyltransferase polymorphic tandem repeat : genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000, 68, 210-9
 
11) McLeod HL, Relling Mv, Liu Q, et al. : Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995, 85, 1897-902
 
12) Szumlanski CL, Honchel R, Scott MC, et al. : Human liver thiopurine methyltransferase pharmacogenetics : biochemical properties, liver-erythrocyte correlation and presence of isozymes. Phamlacogenetics 1992, 2, 148-59
 
13) Woodson LC, Dunnette JH, Weinshilboum RM : Phamacogenetics of human thiopurine methyhransferase : kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982, 222, 174-81
 
14) Evans WE : Pharmacogenetics of thiopurine S-methyhransferase and thiopurine therapy. Ther Drug Monit 2004, 26, 186-91
 
15) Evans WE : Thiopurine S-methyltransferase : a genetic polymorphism that affects a small number of drugs in a big way. Phamacogenetics 2002, 12, 421-3
 
16) Relling MV, Hancock ML, Rivera GK, et al. : Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999, 91, 2001-8
PubMed
17) Fleming RA, Milano G, Thyss A, et al. : Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992, 52, 2899-902
 
18) Wei X, McLeod HL, McMurrough J, et al. : Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracihoxicity. J Clin Invest 1996, 98, 610-5
PubMed
19) Diasio RB, Beavers TL, Carpenter JT : Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracn-induced toxicity. J Clin Invest 1988, 81, 47-51
 
20) Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. : Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency : high prevalence of the IVS14+1g > a mutation. Int J Cancer 2002, 101, 253-8
 
21) van Kuilenburg AB, Haasjes J, Richel, DJ, et al. : Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity : identification of new mutations in the DPD gene. Clin Cancer Res 2000, 6, 4705-12
PubMed
22) Okuda H, Ogura, K, Kato, A, et al. : A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998, 287, 791-9
 
23) Johnson MR, Hageboutros A, Wang, K, et al. : Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-nuorouracil. Clin Cancer Res 1999, 5, 2006-11
 
24) van Kuilenburg, A. B., Muller, E. W., Haasjes, J., et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil : frequency of the common IVSI4+1G > A mutation causing DPD deficiency. Clin Cancer Res 2001, 7, 1149-53
 
25) Maring JG, van Kuilenburg AB, Haasjes., et al. : Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002, 86, 1028-33
 
26) Van Kuilenburg AB, Meinsma R, Zoetekouw L et al. : High prevalence of the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002, 12, 555-8
 
27) Collie-Duguid ES, Etienne MC, Milano G, et al. : Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000, 10, 217-23
 
28) Wei X, Elizond, G, Sapone A., et al. : Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998, 51, 391-400
 
29) Relling MV, Dervieux T : Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001, 1, 99-108
 
30) Fisher MB, Vandenbranden M, Findlay K, et al. : Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity : relationship between UGT1Al promoter genotype and variability in a liver bank. Pharmacogenetics 2000, 10, 727-39
 
31) Bosma PJ, Chowdhury JR., Bakker C, et al. : The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995, 333, 1171-5
PubMed
32) Iyer L, Das S, Janisch L, et al. : UGTlAl*28 polymorphism as a deteminant of irinotecan disposition and toxicity. Phamlacogenomics J 2002, 2, 43-7
 
33) Ando Y, Saka H, Ando M, et al. : Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res 2000, 60, 6921-6
PubMed
34) Beutler E, Gelbart T, Demina A : Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter : a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998, 95, 8170-4
 
35) Ratain MJ, Mic, R, Berezin F, et al. : Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993, 53, 2304-8
 
36) Watson MA, Stewart RK, Smith GB, et al. : Human glutathione S-transferase P1 polymorphisms : relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998, 19, 275-80
 
37) Sweeney C, McClure GY, Fares MY, et al. : Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000, 60, 5621-4
 
38) Stoehlmacher J, Park DJ, Zhang W, et al. : Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002, 94, 936-42
 
39) Furuta T, Takashima M, Shirai N, et al. : Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharrnacol Ther 2000, 67, 684-9
 
40) Dalen P, Dahl ML, Eichelbaum M, et al. : Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999, 9, 697-706
 
41) Takada K, Arefayene M, Desta Z, et al. : Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004, 50, 2202-10
PubMed
42) Daigo S, Takahashi Y, Fujieda M, et al. : A novel mutant allele of the CYP2A6 gene (CYP2A6*ll) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002, 12, 299-306
 
43) Dai D, Zeldin D C, Blaisdell JA, et al. : Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11, 597-607
 
44) Doyle LA, Ross DD : Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22, 7340-58
 
45) Kruh GD, Belinsky MG : The MRP family of drug efflux pumps. Oncogene 2003, 22, 7537-52
 
46) Volk EL, Schneider E : Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003, 63, 5538-43
 
47) Honjo Y, Hrycyna CA, Yan QW, et al. : Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001, 61, 6635-9
 
48) Nishizato Y, Ieiri I, Suzuki H, et al. : Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes : consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003, 73, 554-65
 
49) Iwai M, Suzuki H, Ieiri I, et al. : Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004, 14, 749-57
 
50) Nozawa T, Minami H, Sugiura S, et al. : Role of Organic Anion Transporter Oatp1b1 (Oatp-C) in Hepatic Uptake of lrinotecan and Its Active Metabolite Sn-38 : In Vitro Evidence and Effect of Single Nucleotide Polymorphisms. Drug Metab Dispos 2004,
 
51) Hoffmeyer S, Burk O, von Richter O, et al. : Functional polymorphisms of the human multidrug-resistance gene : multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97, 3473-8
 
52) Marzolini C, Paus E, Buclin T, et al. : Polymorphisms in human MDR1 (P- glycoprotein) : recent advances and clinical relevance. Clin Phammacol Ther 2004, 75, 13-33
 
53) Sparreboom A., Gelderblom H, Marsh S, et al. : Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin Pharmacol Ther 2004, 76, 38-44
 
54) Kondo C, Suzuki H, Itoda M, et al. : Functional analysis of SNPs variants of BCRP/ABCG2. Phaml Res 2004, 21, 1895-903
 
55) Kobayashi D, Ieiri I, Hirota T, et al. : Functional assessment of abcg2 (bcrp) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005, 33, 94-101
 

V. 化学療法時の注意点

P.143 掲載の参考文献
1) 日本医薬情報センター編 : 日本医薬品集第27版. (株) じほう, 2004.
 
2) 吉田清一監修 : がん化学療法の有害反応対策ハンドブック第4版. 先端医学社, 2004.
 
3) 佐々木常雄監修 : 癌化学療法副作用対策のベストプラクティス. 照林社, 2004.
 
4) 西條長宏監修 : 抗悪性腫瘍薬ハンドブック. 中外医学社, 2000.
 
P.148 掲載の参考文献
1) Coiffier B, Lepage E, Briere J, et al : CHOP chemotherapy plus retuximab compares with CHOP alone in elderly patients with diffuse large cell-B-cell lymphoma. N Engl J Med 346 : 235-242, 2002.
 
2) Lyman GH, Dale DC, Friedberg J, et al : Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma : anationwide study. J Clin Oncol 22 : 1-10, 2004.
 
3) Kahn SB, Begg CB, Mazza JJ, et al : Full dose versus attenuated dose daunorubicin, cytosinearabinoside and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 2 (suppl 8) : 865-870, 1984.
 
4) Buchner T, Hiddemann W, Wormann B, et al : Daunorubicin 60 instead of 30mg/sqm improves response and survival in elderly patients with AML. American Society of Hematology, 39th Annual Meeting, 1997.
 
5) Tirelli U, Erranta D, Van Glabbeke M, et al : CHOP is the standard regimen in patients>70 years of age with intermediate-grade and high grade non-Hodgkin's lymphoma : Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group 16 : 27-34, 1998.
 
6) Pfreudschuh M, Trumper L, Kloess M, et al : Two-weelky or 3-weekly CHOPchemotherapy with or without etoposide for the treatment of eiderly patients with aggressive lymphoma : results of the NHL-B2 trial of the DSHNHL. Blood 104 : 634-641 : 2004.
PubMed
7) Mori M, Niitsu N, Takagi T, et al : Reduced dose CHOP therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 41 : 359-366, 2001.
PubMed
P.153 掲載の参考文献
1) 癌化学療法ハンドブック第4版 (古江尚ほか訳), メディカル・サイエンス・インターナショナル, 2003.
 
2) Sachs B, Haider S, Balaraman R, et al : Hepatotoxicity of chemotherapy. Expert. Opin Drug Saf 1 : 339-353, 2002.
PubMed
P.158 掲載の参考文献
1) Hughes WT, et al : 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 : 730-751, 2002.
PubMed
2) Ozer H, et al : 2000 update of recommendations for the use of hematopoietic colony-stimulating factors : Evidence-based, clinical practice guidelines. J Clin Oncol 18 : 3558-3585, 2000.
PubMed
3) Ohno R, et al : Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia : a double-blind controlled study. J Clin Oncol 15 : 2954-2965, 1997.
PubMed
4) Rizzo J D, et al : Use of epoetin in patients with cancer : evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100 : 2303-2320, 2002.
 
5) 厚生省 : 血液製剤の使用指針. 厚生省医薬安全局長通知, 医薬発第715号, 2000.
 
6) 厚生省薬務局 : 血小板製剤の適正使用について. 1994.
 
7) 半田誠血小板製剤. 日内会誌 93 : 1308-1314, 2004.
 
8) Schiffer CA, et al : Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 : 1519-1538, 2001.
 
9) Gralla RJ, et al : Recommendations for the use of antiemetics : evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17 : 2971-2994, 1999.
 
P.164 掲載の参考文献
1) Hoppe R : Hodgkinユs disease : complications of therapy and excess mortality. Ann Oncol 8 (suppl 1) : 115-118, 1997.
 
2) Brunning RD, et al : Acute myeloid leukemias and myelodysplastic syndromes, therapy related (Jaffe ES, et al. ed), World health organization classification of tumors. Pathology and genetics, Tumor of Haematopoietic and lymphoid tissues. pp89-91, Lyon, IARC press, 2001.
 
3) Rosenberg SA : The treatment of Hodgkinユs disease. Ann Oncol 5 (suppl 2) : 17-21, 1994.
 
4) Sears JD, et al : Definitive irradiation in the treatment of Hodgkin's disease : analysis of outcome, prognostic factors, and long term complications. Cancer 79 : 145-151, 1997.
PubMed
5) Swerdlow AJ, et al : Risk of sccond primary canccrs aftcr Hodgkin's disease by type of treatment : analysis of 2826 patients in the British National Lymphoma lnvestigation. Br Med J 304 : 1137-1143, 1992.
 
6) Hancock SL, et al : Breast cancer after treatment of Hogkin's disease. J Natl Cancer Inst 85 : 25-31, 1993.
 
7) Horning SJ, et al : Effect of treatment for Hodgkin's disease on pulmonary function : results of prospective study. J Clin Oncol 12 : 297-305, 1994.
PubMed
8) Cheson BD, et al : Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17 : 2454, 1999.
PubMed
9) Vicki AM, et al : Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with Fludarabine and Chlorambucil : results of an intergroup study, Cancer and leukemia group B 9011. J Clin Oncol 20 : 3878-3884, 2002.
 
10) Kantarjian HM, et al : Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14 : 435-443, 1987.
PubMed
11) Kantarjian HM, et al : Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 7 : 81-107, 1993.
PubMed
12) Takeyama K, et al : Therapy-related leukemia and myelodysplastic syndrome ; a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 71 : 144-152, 2000.
PubMed
13) I Yakoub-Agha, et al : Allogenic bone marrw treasplantation for therapy-related myelodyspiastic syndrome and acute myeloid leukemia : a long-term study of 70 patientsミreport of the French society of bone marrow transplantation. J Clin Oncol 18 : 963-971, 2000.
 
14) Nagler A, et al : Second allogeneic stem celltransplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies fo110wing autologous transplantation. Exp Hematol 28 : 1096-1104, 2000.
PubMed
15) Alan BA, et al : Fiudarabine-related myeloid leukemia. JCO 2003. 99. XXX
 
16) 鵜池直邦 : Nucleoside analog投与例における二次がんの発生. 血液・腫瘍科 41 : 347-353, 2000.
 
17) Pedersen-Bjergaard J, et al : High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 11 : 1654-1660, 1997.
PubMed
18) Micallef INM, et al : Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell g. upport for lymphoid malignancies. J Clin Oncol 18 : 947-955, 2000.
 
19) Caligiuri MA, et al : Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58 : 55-59, 1998.
PubMed
20) Caligiuri MA, et al : Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56 : 1418-1425, 1996.
PubMed

VI. がん患者のQOL向上のために

P.169 掲載の参考文献
1) 柏木哲夫 : 死にゆく患者の心に聴く. 末期医療と人間理解. 中山書店, 1996.
 
2) 柏木哲夫 : 死を看取る医学. NHK出版, 1997.
 
3) 柏木哲夫 : ターミナルケアとホスピス. 大阪大学出版会, 2001.
 
4) 柏木哲夫 : 癒しのターミナルケア. 最新医学社, 2002.
 
P.173 掲載の参考文献
1) 山脇成人監修, 内富庸介編集 : サイコオンオンコロジー がん医療における心の医学. 診療新社. 1997
 
1) 内富庸介 : 第9回がんについての市民公開講演会記録「がんとストレス」, がん医療の現在, 医事出版社, 東京, pp5-18, 2001
 
2) 明智龍男 : がんとこころのケア. NHKブックス. 2003
 
P.179 掲載の参考文献
1) Clinical Practice Guideline No. 9 ; Management of Cancer Pain, U. S. Department of Health and Human Survices 14 : 1994.
 
2) Bonica JJ : Cancer Pain ; Current Status and Future Needs (in Bonica JJ, ed). The Management of Pain, 2nd edition. pp400-455, Philadelphis, Lea & Febiger, 1990.
 
3) Twycross RG, Lack SA : Symptom Control in Far Advanced Cancer : Pain Relief. pp 117-148, Pitman, 1983.
 
4) Matoba M, Goto F : Therapeutic Effects of Antidepressants and Anticonvulsants for Neuropathic Pain in Cancer Patients. Pain Research 9 : 31-39, 1994.
 
5) 的場元弘 : がん性疼痛に対するNSAIDsム効果を十分に引き出すための理解. ターミナルケア 6 : 540, 1996.
 
6) Manara L, Bianchi G, et al : Inhibition of gastrointestineal transit by morphine in rats results primarily from direct action on gut opioid sites. J Pharmacol Exp Ther 237 : 945-949, 1986.
 
7) Twycross RG : Pain Relief in Advanced Cancer. pp307-331, Churchill Livingstone, 1994.
 
8) Twycross RG, LackS A : Symptom Control in Far Advanced Cancer : Pain Relief. pp167-189, Pitman, 1983.
 
9) Chen ZR, Irvine RJ, Somogyi AA, et al : Mu receptor binding of some commonly used opioids and their motabolites. Life Sci 48 : 2165-2171, 1991.
 
10) Heiskanen T, Olkkola KT, Kalso E : Effects of blocing CYP2D6 on the phar nacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64 : 603-611, 1998.
 
11) 的場元弘 : 抗痙攣薬, 抗うつ薬, ステロイドの癌疼痛に対する適応. ペインクリニック 19 : 687-694, 1998.
 
12) 的場元弘 : 鎮痛補助薬の使い方. 緩和医療 1 : 56-64, 2000 ; ペインクリニック 21 : 824-830, 2000.
 
P.183 掲載の参考文献
1) 山本信之, 福岡正博 : 進行肺がん化学療法のガイドライン. がんと化学療法 29 : 985-1007, 2002.
 
2) Non-small Cell Lung Cancer Collaborative Group : Chemotherapy in non-small cell lung cancer : a meta-analysis using updated date on individual patients from 52 randomised clinical trials. BMJ 311 : 899-909, 1995.
 
3) 岡崎美樹, 梅田文一 : 進行肺がん症例に対する外来化学療法. がんと化学療法 10 : 1391-1395, 2001.
 
4) Oshita F, Kurata T, Kasai T, et al : Prospective evaluation of the feasibility of cisplatin based chemotherapy for eldely lung cancer patients with normal organ functions. Jpn J Cancer Res 86 : 1198-1202, 1995.
 
5) Schiller JH, Harrington D, Belani CP, et al : Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N England J Med 346 : 92-98, 2002.
 
6) Sweeney CJ, Zhu J, Sandler AB, et al : Outcome of patients with a performans status of 2 in Eastan Cooperative Oncology Group study E 1594. A phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92 : 2639-2647, 2001.
 
7) 山本昇 : 化学療法薬物有害反応の対策, Third Edition. 臨床腫瘍内科学 : 1136-1150, 2004.
 
8) Coates A, Abraham S, Kayae SB, et al : On the receiving end-patients perception of the side-effects of cancer chemotherapy. Eur J cancer Clin Oncology 19 : 202-208, 1983.
 
9) 有吉寛 : がん化学療法における副作用とその対策. エビデンスに基づいたがん化学療法ハンドブック : 326-333, 2004.
 
10) Douglas EP : Oral toxicity of chemotherapeutic agents. Semin Oncol 19 : 478-491, 1992.
 
11) Berger AM, et al : Adverse effects of treatment. In Devita VT, et al : Cancer, principles and practice of oncology. 6th ed. Lippincott-Raven, 2869-2893, 2001.
 
12) Andrews PL and Hawthron J : The neurophysiology of vomiting. Clin Gastroenterol 2 : 141, 1988.
 
13) Gralla RJ, Osoba D, Kris MG, et al : Recimmendations for the use of antiemetics : Evidence-based, clinical practice guidelines. J clin Oncol 17 : 488, 1994.
 
14) Ohe Y, Sasaki Y, Shinkai T, et al : Phase I study and phammacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84 : 972-974, 1992.
PubMed
15) Bodey GP, Buckley M, Sathe YS, et al : Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intem Med 64 : 328-340, 1966.
 
16) Ozer H, Armitage JO, Benett CL, et al : 2000 Update of Recommendations for the use of hematopoietic colony-stimulating factors : evidence-based, clinical practice gidelines. J Clin Oncol 18 : 3558-3585, 2000.
 
P.190 掲載の参考文献
1) 高橋慶一, 森武生, 山口達郎, ほか : 特集 : 癌治療における有害反応対策 ; 在宅医療と有害反応対策. 日本臨牀 61 : 929-936, 2003.
 
2) 高橋慶一 : 特集 : 最新ハイテク在宅医療機器材料ガイド ; 在宅悪性腫瘍化学療法におけるハイテク医療機器の使用経験. JJPEN 24 : 464-466, 2002.
 
3) 高橋慶一, 森武生, 山口達郎, ほか : 大腸癌肝転移に対する在宅持続肝動注療法の留意点. 癌と化学療法29 (Suppl III) : 480-483, 2002.
 
4) 高橋慶一, 森武生, 大植雅之, ほか : 在宅化学療法における薬物有害反応対策. 癌と化学療法 29 : 1311-1318, 2002.
Medical*Online
P.195 掲載の参考文献
1) 川越博美, 水田哲明 : 「在宅ホスピスケアの基準」についての解説. 臨床看護, 24 : 1125-1129, 1998
 
2) 田中菜奈子 : がん患者の看取りに対する介護者の気持ち. 家庭で看取るがん患者 : 在宅ホスピス入門. 川越厚・編メヂカルフレンド社, 東京, 1991, pp17-19
 
3) 川越厚, 辻彼南雄, 佐藤智 : 在宅ホスピスにおける症状コントロール. 日癌治 27 : 1993-2000, 1992
 
4) Bonica, J. J. : Treatment of cancer pain : Current status and future needs. In Advances in Pain Reseach and Therapy, Fields, H. L, Dubner, R. and Cervero, F. (eds.), Raven Press. New York, 1985, Vol. 9, pp589-616
 
5) World Health Orgnization : Cancer Pain Relief, WHO, Geneve, 1986. 世界保健機関編, がんの痛みからの解放, 武田文和訳, 金原出版, 東京, 1987
 
6) Sauders, C. M. : The management of terminal illness, Hospltal Medicine Publications, London, 1967
 
P.201 掲載の参考文献
1) Steptoe PC, Edwards RG : Birth after the reimplantation of a human embryo. Lancet 2 : 366, 1978.
PubMed
2) Palermo G, Joris H, Devroey P, et al : Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 340 : 17-18, 1992.
PubMed
3) Trounson A, Mohr L : Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 305 : 707-709, 1983.
PubMed
4) Chen C : Pregnancy after human oocyte cryopreservation. Lancet 1 : 884-886, 1986.
PubMed
5) Fischer R, Baukloh V, Naether OG, et al : Pregnancy after intracytoplasmic sperm injection of spermatozoa extracted from frozenthawed testicular biopsy. Hum Reprod 11 : 2197-2199, 1996.
PubMed
6) Hovatta O, Silye R, Krausz T, et al : Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants. Hum Reprod 11 : 1268-1272, 1996.
PubMed
7) Smitz J, Cortvrindt R : Follicle culture after ovarian cryostorage. Maturitas 30 : 171-179, 1998.
PubMed
8) Donnez J, Dolmans MM, Demylle D, et al : Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364 : 1405-1410, 2004.
PubMed
9) Oktay K : Ovarian tissue cryopreservation and transplantation : preliminary findings and implications for cancer patients. Hum Reprod Update 7 : 526-534, 2001.
PubMed
10) Howell S, Shalet S : Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 27 : 927-943, 1998.
PubMed
11) DeSantis M, Albrecht W, Holt1 W, et al : Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 83 : 864-865, 1999.
 
12) Sonmezer M, Oktay K : Fertility preservation in female patients. Hum Reprod Update 10 : 251-266, 2004.
PubMed
13) Yarbro CH, Perry MC : The effect of cancer therapy on gonadal function. Semin Oncol Nurs 1 : 3-8, 1985.
PubMed
14) Baruch J, Benjamin S, Treleaven J, et al : Male sexual function following bone marrow transplantation. Bone Marrow Transplant 7 (Suppl 2) : 52, 1991.
 
15) Nijman JM, Schraffordt Koops H, Oldhoff J, et al : Sexual function after surgery and combination chemotherapy in men with disseminated nonseminomatous testicular cancer. J Surg Oncol 38 : 182-186, 1988.
PubMed
16) Broeckel JA, Thors CL, Jacobsen PB, et al : Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treat 75 : 241-248, 2002.
PubMed
17) Gosden RG, Wade JC, Fraser HM, et al : Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod 12 : 2483-2488, 1997.
PubMed
18) Schover LR : Sexuality and Fertility After Cancer. New York, NY : John Wiley and Sons, 1997.
 
19) Wallace WH, Shalet SM, Crowne EC, et al : Ovarian failure following abdominat irradiation in childhood : natural history and prognosis. Clin Oncol (R Coll Radiol). 1 : 75-79, 1989.
 
20) Stillman RJ, Schinfeld JS, Schiff I, et al : Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 139 : 62-66, 1981.
PubMed
21) Critchley HO, Bath LE, Wallace WH : Radiation damage to the uterus-review of the effects of treatment of childhood cancer. Hum Fertil (Camb). 5 : 61-66, 2002.
 
22) Green DM, Whitton JA, Stovall M, et al : Pregnancy outcome of female survivors of childhood cancer : a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 187 : 1070-1080, 2002.
PubMed
23) Green DM, Peabody EM, Nan B, et al : Pregnancy outcome after treatment for Wilms tumor : a report from the National Wilms Tumor Study Group. J Clin Oncol 20 : 2506-2513, 2002.
 
24) Lamb MA, Woods NF : Sexuality and the cancer patient. Cancer Nurs 4 : 137-144, 1981.
PubMed
25) Chorost MI, Weber TK, Lee RJ, et al : Sexual dysfunction, informed consent and muitimodality therapy for rectal cancer. Am J Surg 179 : 271-274, 2000.
 
26) Menick GS, Butler WM, Galbreath RW, et al : Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52 : 893-902, 2002.
 
27) Brenner H, Kaatsch P, Burkhardt-Hammer T, et al : Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer 92 : 1977-1983, 2001.
PubMed
28) Jemal A, Murray T, Samuels A, et al : Cancer statistics, 2003. CA Cancer J Clin 53 : 5-26, 2003.
PubMed
29) Pui CH, Cheng C, Leung W, et al : Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349 : 640-649, 2003. Erratum in : N Engl J Med 349 : 1299, 2003.
 
30) Robison LL, Bhatia S : Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 122 : 345-359, 2003.
PubMed
31) Overgaard M, Hansen PS, Overgaard J, et al : Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breag. t Cancer Cooperative Group 82b Trial. N Engl J Med 337 : 949-955, 1997.
 
32) Colombo N, Parma G, Bocciolone L, et al : Medical therapy of advanced malignant epithelial tumours of the ovary. Forum (Genova) 10 : 323-332, 2000.
PubMed
33) Boran N, Tulunay G, Caliskan E, et al : Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet, 2004.
PubMed
34) Struewing JP, Hartge P, Wacholder S, et al : The risk of cancer associated with specific mutations of BRCAl and BRCA2 among Ashkenazi Jews. N Engl J Med 336 : 1401-1408, 1997.
 
35) Liede A, Narod SA : Hereditary breast and ovarian cancer in Asia : genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20 : 413-424, 2002.
PubMed
36) Struewing JP, Watson P, Easton DF, et al : Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr : 33-35, 1995.
PubMed
37) Gladstone DE, Prestrud AA, Pradhan A, et al : High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 11 : 405-410, 2002.
PubMed
38) Dillman RO, Davis RB, Green MR, et al : A comparative study of two different doses of cytarabine for acute myeloid leukemia : a phase III trial of Cancer and Leukemia Group B. Blood 78 : 2520-2526, 1991.
 
39) Thibaud E, Rodriguez-Macias K, Trivin C, et al : Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 21 : 287-290, 1998.
PubMed
40) Blumenfeld Z, Avivi I, Linn S, et al : Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releag. ing hormone agonist in parallel to chemotherapy. Hum Reprod 11 : 1620-1626, 1996.
 
41) Waxman JH, Ahmed R, Smith D, et al : Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19 : 159-162, 1987.
 
42) 久保春海, 平成13・14年度倫理委員会・登録・調査小委員会 : 平成13・14年度倫理委員会・登録・調査小委員会報告. 平成12・13年分の体外受精・胚移植等の臨床実施成績及び平成15年3月における登録施設名 : 日本産科婦人科学会雑誌 (0300-9165) 55巻10号 : 1272-1306, 2003.
 
43) Katayama KP, Stehlik J, Kuwayama M, et al : High survival rate of vitrified human oocytes results in clinical pregnancy. Fertil Steril 80 : 223-224, 2003.
PubMed
44) Tucker MJ, Wright G, Morton PC, et al : Birth after cryopreservation of immature oocytes with subsequent in vitro maturation. Fertil Steril 70 : 578-579, 1998.
PubMed
45) Wu J, Zhang L, Wang X : In vitro maturation, fertilization and embryo development after ultrarapid freezing of immature human oocytes. Reproduction 121 : 389-393, 200L
 
46) Oktay K, Aydin BA, Karlikaya G : A technique for laparoscopic transplantation of frozen-banked ovarian tissue. Fertil Steril 75 : 1212-1216, 2001.
PubMed
47) Oktay K, Economos K, Kan M, et al : Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 286 : 1490-1493.
 
48) Radford JA, Lieberman BA, Brison DR, et al : Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet 357 : 1172-1175, 2001.
PubMed

VII. がんの予防と早期発見

P.212 掲載の参考文献
1) 小林博, がんの予防 新版, 岩波書店, 1999.
 
2) 小林博, がんに挑む がんに学ぶ, 岩波書店, 2000.
 
3) 大野秀樹・及川恒之・石川直方編, Q&A運動と遺伝, 大修館書店, 2001.
 
4) 垣添忠生, がんの最新医療, 岩波書店, 2004.
 
5) 小林博・近藤喜代太郎, がんの健康科学, (財) 放送大学教育振興会, 2004.
 
6) 富永祐民, がん検診の到達目標, BIO Clinica 19 (11) 41-45, 2004.
 
7) Tajima K., Kuroishi T., Oshima A., Cancer Mortality and Morbidity Statistics, Japan Scientific Societies Press, 2004.
 
8) Tominaga S., Cancer Control Strategy and Perspectives : Experience in Japan, Proceeding of the 54th Annual Meeting of the Korean Association of Preventive Medicine Special lecture, Seoul, 2004.
 
9) Isabel dos Santos Silva, Cancer Epidemiology : Principles and Methods, International Agency for Research on Cancer, 1999.
 
10) 津金昌一郎, がんになる人 ならない人 科学的根拠に基づくがん予防, ブルーバックス講談社, 2004.
 
11) 津金昌一郎, 疫学研究と予防研究, 日本がん予防研究会News Letter No. 42, 2004.
 
12) Prentice R. L. et al, Nutrition and Physical Activity and Chronic Diseases Prevention : Research Strategies and Recommendations, J Nat Cancer Int 96 : 1276-1287, 2004.
 
13) Wingo P. A. et al : Cancer Incidence and Mortality, 1973-1995, A Report Card for the U. S., Cancer 82 : 1197-1270, 1998.
 
14) Ries L. A. G et al : Annual Report to the Nation on the Status of Cancer, 1973-1997, with a Special Section on Colorectal Cancer, Cancer 88 : 2398-2424, 2000.
 
15) Wingo PA et al : Annual Report to the Nation on the Status of Cancer, 1973-1996, with a Special Section on Lung Cancer and Tobacco Smoking, J. Nat Cancer Inst 91 : Special Article 675-690, 1999.
 
16) 大島明, 喫煙をめぐる日本と世界の動向, 「呼吸器科」第6巻6号特集, 喫煙と呼吸器疾患, 印刷中
 
17) Doll R., Peto R., Boreham J., Sutherland L, Moritality in relation to smoking : 50 yearsl observations on male British doctors, BMJ, doi : 10. 1136/bmj. 38142554479. AE 1-9, 2004.
 
18) 福田勝洋, 日本公衆衛生学会による "「たばこのない社会」の実現に向けて" 宣言までの経緯, 日本公衛誌 ; 48 : 425-428, 2001.
 
19) 厚生省編, 喫煙と健康, (財) 健康・体力づくり事業財団, 1993.
 
20) 藤枝正輝・山崎浩史・鎌滝哲也, 喫煙による発癌リスクと薬物代謝酵素遺伝子多型Molecular Medicine 39 臨時増刊がんゲノム学 266-272, 2002.
 
21) 山崎浩史・千葉逸朗・Topen Zeki・藤枝正輝・柴田敏之・有吉範高・小林博・鎌滝哲也, CPY2A6遺伝子欠損と発がんリスク : 噛みタバコと口腔がん, 日本癌学会総会記録 P48, 2002.
 
22) 浜島信之, 遺伝子多型とがん発生リスク, 癌と化学療法 31 : 853-857, 2004.
Medical*Online
23) 国立がんセンター監修, がんを防ぐための12ヵ条, (財) がん研究振興財団
 
24) Hakama M., Beral V., Cullen J. W., Parkin D. M, , Evaluating effectiveness of primary prevention of cancer, International Agency for Research on Cancer, 1990.
 
25) World Cancer Research Fund, Food, Nutrition and the Prevention of Cancer : a global perspective, American Institute for Cancer Research, 1997.
 
26) 大澤俊彦・大東肇・吉川敏一監修, がんの予防食品, シーエムシー, 1999.
 
27) 森秀樹, 「病理」からみた「ガン予防」, ガン予防食品フードファクターの予防医学への応用, 大沢俊彦, 大東肇, 吉田俊一監修, シーエムシー 99-106, 1999.
 
28) 日本がん疫学研究会がん予防指針検討委員会編著 : 生活習慣と主要部位のがん, 九州大学出版会, 1998.
 
29) 前田浩, 野菜はガン予防に有効か : 酸素ラジカルを巡る諸問題, 菜根出版, 1995.
 
30) Cheng J. L., Ogawa K., Kuriki K., Yokoyama Y., Kamiya T., Seno K., Okuyama H., Wang J. W., Luo C. H., Fujii T., Ichikawa H., Shirai T., and Tokudome S. Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors. Cancer Lett. 193 : 17-24, 2003.
 
31) 西野輔翼編集, 週刊医学のあゆみ「癌の化学予防最前線」, 医歯薬出版, 2003.
 
32) 津田洋幸・関根一則・飯郷正明, ラクトフェリンによる発がん予防とその機序の解析, Foods & Food Ingredients J of Japan No200-別冊, 2002.
 
33) Wakabayashi K, NSAIDs as Cancer Preventive Agents, Asian Pacific Cancer Prevention 1 : 97-113, 2000,
 
34) Ishikawa H., Chemoprevention of carcinogenesis in familial tumors, Jap. J. Clrin Oncology, 印刷中
 
35) Harris PR, Mobley HL, Perez-Perez GI, Blaser Mj, Smith PD. : Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. Gastroenterology, 111 (2) : 419-425, 1996.
PubMed
36) Tazawa H., Okada F., Kobayashi T., Tada M., Mori Y., Une Y., Sendo F, Kobayashi M, and Hosokawa M. : Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells : Implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol. . 163 (6) : 2221-2232, 2003.
 
37) Okada F. : Inflammation and free radicals in tumor development and progression. Redox Report, 7 : 357-368, 2002.
PubMed
38) Habelhah H., Okada F., Nakai K., Choi S. K., Hamada J-L, Kobayashi M. and Hosokawa M. : Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells : possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K. Cancer Immunol Immunother, 46 : 338-344, 1998
 
39) 細川真澄男, 癌細胞の悪性化のBRMによる予防, Biotherapy 10 ; 1231-1237, 1996.
 
40) James F. Mckenzie Jan L. Jurs, Planning, Implementing, and Evaluating Health Promotion Programs, Macmillan Publishing Company, 1993.
 
41) Hugh Hawes, Health Promotion in our Schools, Child-to-Child Trust, 1997.
 
42) 新井宏朋・丸地信弘・山根洋右・島内節・岩永俊博編集, 健康の政策科学, 医学書院, 1997.
 
43) Geoffrey Rose水嶋春遡ほか訳, 予防医学のストラテジー, 医学書院, 1998.
 
44) World Health Organization, Local Action Creating Health Promotion Schools, World Health Organization, 2000.
 
45) Chiba L Prevention of betel quid chewers' oral cancer in the Asian-Pacific area, Asian Pacific J. cancer Prev., 2 : 263-269, 2001.
 
46) Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, Sevgican F, Muthumala M, Kobayashi H, Kamataki T., CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka., Carcinogenesis, Apr ; 23 (4) : 595-8, 2002.
PubMed
47) 北海道白血病登録委員会, 小児白血病に生下時巨大児が多い?, 医学のあゆみ 79 : 364-354, 1971.
 
48) Matsunaga K, Iijima H, Kobayashi H, Neonatal inoculation with a protein-bound polysaccharide PSK increases resistance of adult animals to challenge with syngeneic tumor cells and reduces azoxymethane-induced precancerous lesions in the colon., J. Cancer Epidemiology, Biomarkers and Prevention 9, 13正3-1322, 2000.
 
49) Kobayashi H, Iijima H, Matsunaga K, Inhibition of AOM colon carcinogenesis by neonatal inoculation of sulindac, and its augmentation by combined use of oral sulindac in adult period, Proceeding of 93th Annual Meeting of American Association for Cancer Research, p. 124, 2002.
 
50) 飯島弘子・松永謙一・小林博, 食品由来機能性物質ウシラクトフェリンおよび担子菌マツタケ由来糖蛋白質の新生児期処置によるAOM誘発ラット大腸前がん病変の抑制について, 日本癌学会総会記事, 第64回総会, 2004.
 
51) 辻一郎, 健康寿命, 春秋社, 1998.
 
52) 辻一郎, のばそう健康寿命, 岩波アクティブ, 2004.
 
P.218 掲載の参考文献
1) 久道茂 : がん検診の適正化に関する調査研究事業「新たながん検診手法の有効性の評価」報告書. 日本公衆衛生協会, 2001.
 
2) 厚生労働省老健局老人保健課長通知 (老老発第0427001号) : 「がん予防重点健康教育及びがん検診実施のための指針」の一部改正について, 2004.
 
3) Tominaga S : An estimate of the potential for cancer prevention in Japan. Asia Pcific J Cancer Prev 2 : 287-292, 2001.
 

VIII. 化学療法の実際

P.223 掲載の参考文献
1) Ohno R, et al : Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer 71 : 3888-3895, 1993.
 
2) Kobayashi T, et al : Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 14 : 204-213, 1996.
 
3) Miyawaki S, et al : No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia : the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 70 : 97-104, 1999.
 
4) Asystematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 103 : 100-109, 1998.
 
5) Bishop J F, et al : A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87 : 1710-1717, 1996.
PubMed
6) Weick J K, et al : A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia : a Southwest Oncology Group study. Blood 88 : 2841-2851, 1996.
 
7) Rai K R, et al : Treatment of acute myelocytic leukemia : a study by cancer and leukemia group B. Blood 58 : 1203-1212, 1981.
 
8) Stein R S : Advances in the therapy of acute nonlymphocytic leukemia. Am J Med Sci 297 : 26-34, 1989.
PubMed
9) Cassileth P A, et al : Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6 : 583-587, 1988.
PubMed
10) Mayer R J, et al : Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 : 896-903, 1994.
 
11) Miyawaki S, et al : Postremission Therapy in Adult Acute Myeloid Leukemia (AML) : A Randomized Comparison of lntensified Consolidation Therapy without Maintenance Therapy Against Conventional Consolidation with Maintenance Therapy-JALSG AML-97 Trial. Blood 104 : 248a, 2004.
 
12) Sakamaki H, et al : Postremission Treatment with Chemotherapy or Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myeloid Leukemia (AML) -JALSG AML-97 Trial., Blood 104 : 632a, 2004.
 
13) Huang M E, et al : Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 : 567-572, 1988.
PubMed
14) Tallman M S, et al : All-trans retinoic acid in acute promyelocytic leukemia : long-terrn outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100 : 4298-4302, 2002.
 
15) Fenaux P, et al : A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94 : 1192-1200, 1999.
PubMed
16) Asou N, et al : All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia : comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 40 Suppl : S30-35, 1997.
 
17) Tobita T, et al : Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90 : 967-973, 1997.
PubMed
18) Soignet S L, et al : United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 : 3852-3860, 2001.
 
19) Hoelzer D, et al : Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71 : 123-131, 1988.
 
20) Larson R A, et al : Afive-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia : cancer and leukemia group B study 8811. Blood 85 : 2025-2037, 1995.
 
21) Durrant I J, et al : Intensification of treatment for adults with acute lymphoblastic leukaemia : results of U K Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 99 : 84-92, 1997.
 
22) Kantarjian H M, et al : Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18 : 547-561, 2000.
PubMed
23) Annino L, et al : Treatment of adult acute lymphoblastic leukemia (ALL) : long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99 : 863-871, 2002.
PubMed
24) Takeuchi J, et al : Induction therapy by frequent administration of doxorubicin with four other drugs, fbllowed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia 16 : 1259-1266, 2002.
PubMed
25) Boissel N, et al : Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 : 774-780, 2003.
 
26) Druker B J, et al : Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 : 1038-1042, 2001.
PubMed
27) Hoelzer D, et al : Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87 : 495-508, 1996.
PubMed
28) Thiebaut A, et al : Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 14 : 1353-1366, 2000.
PubMed
29) O'Brien S G, et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 : 994-1004, 2003.
PubMed
30) Hughes T P, et al : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 : 1423-1432, 2003.
 
31) Talpaz M, et al : Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia : results of a phase 2 study. Blood 99 : 1928-1937, 2002.
PubMed
32) Sawyers C L, et al : Imatinib induces hematologic and cytogenetic reg. ponses in patients with chronic myelogenous leukemia in myeloid blast crisis : results of a phase II study. Blood 99 : 3530-3539, 2002.
 
33) Rai K R, et al : Clinical staging of chronic lymphocytic leukemia. Blood 46 : 219-234, 1975.
PubMed
34) Chronic lymphocytic leukaemia : proposals for a revised prognostic staging system. Report from the International Workshop on CLL. Br J Haematol 48 : 365-367, 1981.
PubMed
35) Cheson B D, et al : National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia : revised guidelines for diagnosis and treatment. Blood 87 : 4990-4997, 1996.
 
P.231 掲載の参考文献
1) Jaffe ES, et al : Pathlogy and genetics of tumours of haematopoietic and lymphoid tissues IARC. Lyon, 2001.
 
2) Canellos GP, et al : Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 : 1478-1484, 1992.
 
3) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 : 987-994, 1993.
PubMed
4) Miller TP, at al : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high grade non-Hodgkin's lymphoma. N Engl J Med 339 : 21-26, 1998.
 
5) Fisher RI, et al : Comparison of a Standard Regimen (CHOP) with Three lntensive Chemotherapy Regimens for Advanced non-Hodgkin's lymphoma. N Eng J Med 328 : 1002-1006, 1993.
 
6) Coffier B, et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med 346 : 235-242, 2002.
 
7) Velasques WS, et al : Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP), Blood 71 : 117-122, 1988.
 
8) Wilson WH, et al : EPOCH chemotherapy : toxicity and efficacy I relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11 : 1573-1582, 1993.
PubMed
9) Jermann M, et al : Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas : results of a phase II study. Ann Oncol 15 : 511-516, 2004.
PubMed
10) Philip T, et al : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Eng J Med 333 : 1540-1545, 1995.
 
11) Milpied N, et al : Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem Cell Support. N Eng J Med 350 : 1287-1295, 2004.
 
12) Shipp MA, et al : Intemational consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas. Report of the July. J Clin Oncol 17 : 423-429, 1999.
 
13) Yamada Y, et al : A new G-CSF-supported combination chemotherapy, LSG 15, for adult T-cell leukemia-1ymphoma : Japan Clinical Oncology Group Study 9303. Br J Hematol 113 : 375-382, 2001.
 
14) Khouri IF, et al : Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation : an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16 : 3803-3809, 1998.
PubMed
15) Neubauer A, et al : Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 17 : 89 (18) : 1350-1355, 1997.
 
P.237 掲載の参考文献
1) 厚生労働省大臣官房統計情報部 (編). 平成13年人口動態統計. 東京, 厚生労働省大臣官房統計情報部, 2003.
 
2) The Reg. earch Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1998 : estimates based on data from 12 population-based cancer registries. Jpn J Clin Oncol 33 : 241-245, 2003.
 
3) Sobue T, et al : Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women : the JPHC study. Int J Cancer 99 : 245-251, 2002.
PubMed
4) 日本肺癌学会 (編) : 肺癌取扱い規約 改訂第6版. 東京, 金原出版, 2003.
 
5) Shepherd FA, et al : Importance of clinical staging in limited small-cell lung cancer : a valuable system to separate prognostic subgroups. J Clin Oncol 11 : 1592-1597, 1993.
PubMed
6) Evidence-based・Medicine (EBM) の手法による肺癌の診療ガイドライン策定に関する研究班 : EBMの手法による肺癌診療ガイドライン. 金原出版, 2003.
 
7) Pignon JP, et al : A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 : 1618-1624, 1992.
PubMed
8) Warde P, Payne D : Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 : 890-895, 1992.
PubMed
9) Takada M, et al : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer : results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20 : 3054-3060, 2002.
 
10) Murray N, et al : Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 : 336-344, 1993.
 
11) Noda K, et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002.
PubMed
12) Hanna NH, et al : Randomized, phase III trial comparing irinotecan/ ciplatin (IP) with etoposide/ciplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 23 : 622s (#LBA7004), 2005.
 
13) Arriagada R, et al : Prophylactic cranial irradiation for patients with small-cell lung cancer in complctc remission. N Engl J Med 341 : 476-484, 1999.
PubMed
14) Arriagada R, et al : Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 : 351-360, 2004.
PubMed
15) Kato H, et al : Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. N Engl J Med 350 : 1713-1721, 2004.
 
16) Schiller JH, et al : Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 : 92-98, 2002.
PubMed
17) Kubota K, et al : The four-arm cooperative study (FACS) for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23 : 616 (#7006), 2004.
 
18) Sandler AB, et al : Randomized, phase II/III trial of panclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC), ; An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. Proc Am Soc Clin Oncol 23 : 1090s (#4), 2005.
 
19) Gridelli C, et al : Chemotherapy for elderly patients with advanced non-small-cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 : 362-372, 2003.
 
20) Takeda K, et al : Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) ; Resultes of a West Japan Thoracic Oncology Group trial (WJTOG 9904). Proc Am Soc Clin Oncol 23 : 623s (#7009), 2005.
 
21) Fossella FV, et al : Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 : 2354-2362, 2000.
 
22) Crino L, et al : Gcmcitabinc as sccond-linc treatment for advanced non-small-cell lung cancer : A phase II trial J Clin Oncol 17 : 2081-2085, 1999.
 
23) Fukuoka M, et al : Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 : 2237-2246, 2003.
PubMed
24) Calvert AH, et al : Carboplatin dosage : prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 : 1748-1756, 1989.
PubMed
25) Chatelut E, et al : Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87 : 573-580, 1995.
PubMed
26) Fukuda M, et al : Phase II Study of Irinotecan Combined with Carboplatin in Previously Untreated Non-Small Cell Lung Cancer. Cancer Chemotherapy and Pharmacology 54 : 573-577, 2004.
PubMed
27) Katayama H, et al : Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-smaH-cell lung cancer. Br J Cancer 90 : 979-984, 2004.
 
28) Oka M, et al : Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer. Eur J Cancer 37 : 1359-1365, 2001.
PubMed
29) Kiura K, et al : Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89 : 795-802, 2003.
PubMed
30) Lynch TJ, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004.
PubMed
31) Paez JG, et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004.
PubMed
32) Perez-Soler R, et al : Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 22 : 3238-3247, 2004.
PubMed
33) Hanna N, et al : Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 : 1589-1597, 2004.
PubMed
34) Kawahara M, et al : Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 : 939-943, 2001.
PubMed
P.242 掲載の参考文献
1) Shrump DS, Altorki NS, Forastiere AA : Cancer ; principles and practice of oncology (In : Devita VT, ed). Cancer of the esophagus. pp1051-1091, Philadelphia, Lippincott-Rava, 2000.
 
2) Ajani JA : Contributions of chemotherapy in the treatment of carcinoma of the esophagus : results and commentary. Semin Oncol 21 : 474-482, 1994.
PubMed
3) Engstrom PF, Lavin PT, Klaassen DJ : Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 67 : 713-715, 1983.
PubMed
4) Ezdinli EZ, Gelber R, Desai DV, et al : Chemotherapy of advanced esophageal carcinoma : Eastern Cooperative Oncology Group experience. Cancer 46 : 2149-2153, 1980.
PubMed
5) Ajani JA, 11son DH, Daugherty K, et al : Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86 : 1086-1091, 1994.
 
6) Muro K, Hamaguchi T, Ohtsu A, et al : A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15 : 955-959, 2004.
PubMed
7) 田口鐵男, 涌井昭, 鍋谷欣一, ほか : 254-S (Cis-diammine glycolate platinum) の消化器癌に対する第II相臨床試験. 癌と化学療法 19 : 483-488, 1992.
 
8) Enzinger P, Kulke M, Clark J, et al : Phase II Trial of CPT-11 in Previously Untreated Patients with Advanced Adenocarcinoma of the Esophagus and Stomach. Proc ASCO 19 : 315a, 2000.
 
9) Coonley CJ, Bains M, Hilaris B, et al : Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final reporL Cancer 54 : 2351-2355, 1984.
PubMed
10) Kelsen D, Hilaris B, Coonley C, et al : Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. Am J Med 75 : 645-652, 1983.
PubMed
11) Hilgenberg AD, Carey RW, Wilkins EW Jr, et al : Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 45 : 357-363, 1988.
PubMed
12) Ajani JA, Ryan B, Rich TA, et al : Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Bur J Cancer 28A : 880-884, 1992.
 
13) Bleiberg H, Conroy T, Paillot B, et al : Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33 : 1216-1220, 1997.
PubMed
14) Scanlon KJ, Newman EM, Lu Y, et al : Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 83 : 8923-8925, 1986.
PubMed
15) Douple EB, Richmond RC : A view of interactions between platinum coodination complexes and ionizing radiation : implication for cancer therapy (ln : Prestayko AW, Crooke ST, Karter SK, eds). In Cisplation : current status and new developments. Orland : FL Academic 125-147, 1980.
 
16) Ilson DH, Kelsen DP : Combined modality therapy in the treatment of esophageal cancer. Semin Oncol 21 : 493-507, 1994.
PubMed
17) Iizuka T, Kakegawa T, Ide H, et al : Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus : a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22 : 172-176, 1992.
PubMed
18) Ilson DH, Ajani J, Bhalla K, et al : Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16 : 1826-1834, 1998.
PubMed
19) Kelsen D, Ginsberg R, Bains M, et al : A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer : a preliminary report. Semin Oncol 24 : Sl9-77-S19-81, 1997.
 
20) Araujo CM, Souhami L, Gil RA, et al : A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 67 : 2258-2261, 1991.
PubMed
21) al-Sarraf M, Martz K, Herskovic A, et al : Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer : an intergroup study. J Clin Oncol 15 : 277-284, 1997.
PubMed
22) Sakai K, Inakoshi H, Sueyama H, et al : Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-f] uorouracil in inoperable esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 31 : 921-927, 1995.
 
23) Poplin EA, Jacobson J, Herskovic A, et al : Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks A pilot trial of continuous infusion 5-fluorouracil with levamisole for a (ljuvant therapy of colon cancer. Cancer 78 : 1851-1856, 1996.
 
24) Ohtsu A, Boku N, Muro K, et al : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17 : 2915-2921, 1999.
PubMed
25) Ura T, Muro K, Shimada K, et al : Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer. Proc ASCO 23 : 316, 2004.
 
26) Hironaka S, Ohtsu A, Boku N, et al : Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T (2-3) N (any) M (0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57 : 425-433, 2003.
 
27) Bedenne P, Michel O, Bouche JP, et al : Randomized phase III trial in locally advanced eg. ophageal cancer. radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc ASCO 21 : 519, 2002.
 
28) Wilke MK, Walz S, Seeber B, et al : Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus : Chemoradiation with and without surgery. Proc ASCO 22 : 1001, 2003.
 
29) Flamen P, Van Cutsem E, Lerut A, et al : Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 : 361-368, 2002.
PubMed
30) Kato H, Kuwano H, Nakajima M, et al : Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184 : 279-283, 2002.
PubMed
31) Ando N, Iizuka T, Ide H, et al : Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus : a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol 21 : 4592-4596, 2003.
 
32) Roth JA, Pass HI, Flanagan MM, et al : Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 96 : 242-248, 1988.
PubMed
33) Schulag P : Preoperative chemotherapy in locarized squamous cell carcinoma of the esophagus : results of a prospective randomized trial. Eur J Cancer 27 : s76, 1991.
 
34) Kok TC, Lanschot JV, Siersema PD : Rotterdam Esopahgeal Tumor Study Group : Neoa (ljuvant chemotherapy in operable esophageal squamous cell cancer : final report of a phase III multicenter randomized controlled trial. Proc ASCO l 6 : 277a, 1997.
 
35) Kelsen DP, Ginsberg R, Pajak TF, et al : Chemotherapy followed by surgery compared with surgery alone f6r localized esophageal cancer. N Engl J Med 339 : 1979-1984, 1998.
 
36) Clark P : Surgical Resection With Or Without Pre-operative Chemotherapy In Oesophageal Cancer : An Updated Analysis Of A Randomised Controlled Trial Conducted By The Uk Medical Research Council Upper Gi Tract Cancer Group. Proc ASCO 20 : 126a, 2001.
 
37) Nygaard K, Hagen S, Hansen HS, et al : Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma : a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16 : 1104-1109 ; discussion 1110, 1992.
PubMed
38) Le Prise E, Etienne PL, Meunier B, et al : A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous ceil carcinoma of the esophagus. Cancer 73 : 1779-1784, 1994.
 
39) Walsh TN, Noonan N, Hollywood D, et al : A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 : 462-467, 1996.
PubMed
40) Bosset JF, Gignoux M, Triboulet JP, et al : Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 : 161-167, 1997.
PubMed
41) Urba SG, Orringer MB, Turrisi A, et al : Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 : 305-313, 2001.
 
P.249 掲載の参考文献
1) Wils J, Klein HO, Wagener DJ, et al : Sequential high-dose methotrexate and fluorouracil combined with doxorubicin : A trial of the European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cooperative Group. J Clin Oncol 9 : 827-831, 1991.
 
2) Kelsen D, Atiq O, Saltz L, et al : FAMTX versus etopside, doxorubicin, and cisplatin : arandom assignment trial in gastric cancer. J Clin Oncol 10 : 541-548, 1992.
 
3) Kim NK, Park YS, Heo DS, et al : A phase III randomized study of 5-fluorouracil and cisplatin versus 5-f] uorouracil, doxorubicin and mitomycin Cversus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71 : 3813-3818, 1993.
 
4) Cullinan SA, Moertel CG, Fleming TR, et al : Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. NCCTG. J Clin Oncol 12 : 412-416, 1994.
 
5) Cocconi G, Bella M, Ziromi S, et al : Fluorouracil, doxorubicin and mitomycin combination versus PFLP chemotherapy in advanced gastric cancer : a prospective randomized trial of the ltalian oncology group for clinical research. J Clin Oncol 12 : 2687-2693, 1994.
 
6) Waters JS, Norman A, Cunningham D, et al : Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer : results of a randomized trial. Br J Cancer 80 : 269-272, 1999.
PubMed
7) Vanhoefer U, Rougler P, Wilke H, et al : Final results of randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer : A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 : 2648-2657, 2000.
 
8) Ohtsu A, Shimada Y, Shirao K, et al : Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresctable, advanced gastric cancer : The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 : 54-59, 2003.
 
9) Takahashi I, Kakeji Y, Emi Y, et al : S-1 in the treatment of advanced and recurrent gastric cancer 6 : 28-33, 2003.
PubMed
10) Baba H, Yamamoto M, Endo K, et al : Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 6 : 45-49, 2003.
PubMed
11) Macdonald JS, Smalley SR, Benedetti J, et al : Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 : 725-730, 2001.
PubMed
12) Nakajima T, Nashimoto A, Kitamura M, et al : Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer : a randomized trial. Lancet 354 : 273-277, 1999.
PubMed
13) Hermans J, Bonenkamp JJ, Boon MC, et al : Adjuvant therapy after curative resection for gastric cancer : meta-analysis of randomized trials. J Clin Oncol 11 : 1441-1447, 1993.
PubMed
14) Ajani JA, Mansfield PF, Janjan N, et al : Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22 : 2774-2780, 2004.
PubMed
P.256 掲載の参考文献
1) Simmonds PC : Colorectal cancer collaborative group : Palliative chemotherapy for advanced colorectal cancer : systematic review and meta-analysis. BMJ 321 : 531-535, 2000.
 
2) Thirion P, et al : Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer : an updated meta-analysis. J Clin Oncol 22 : 3766-3775, 2004.
PubMed
3) Petrelli N, et al : The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma : a prospective randomized phase III trial. Gastrointestinal tumor study group. J Clin Oncol 7 : 1419-1426, 1989.
 
4) Poon MA, et al : Biochemical modulation of fluorouracil : evidence of significant improvement of f urvival and quality of life in patients with advanced carcinoma. J Clin Oncol 7 : 1407-1418, 1989.
 
5) De Gramont A, et al : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol 15 : 808-815, 1997.
PubMed
6) Kohne CH, et al : Randmized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer : European organization of research and treatment of cancer gastrointestinal group study 40952. J Clin Oncol 20 : 3721-3728, 2003.
 
7) Toxicity of fiuorouracil in patients with advanced colorectal cancer : effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16 : 3537-3541, 1998.
 
8) Ozer H, et al : 2000 update of recommendations for the use of hematopoietic colony-stimulating factors : evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18 : 3558-3585, 2000.
 
9) 宇良敬 : 転移性再発大腸癌150例に対する5FU+1-LV療法の治療成績 : 第40回日本癌治療学会抄録集. PS49-1, 2002.
 
10) Cunningham D, et al : Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 : 1413-1418, 1998.
PubMed
11) Rougier P, et al : Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 : 1407-1412, 1998.
PubMed
12) Mertens WC, et al : Improving the care of patients with regard to chemotherapy-induced nausea and emesis : the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21 : 1373-1378, 2003.
PubMed
13) Inoue A, et al : Randomized study of dexamethasone treatment for delayed emesis, anorcxia and fatigue induced by irinotecan. Support Care Cancer 11 : 528-532, 2003.
PubMed
14) Abigerges D, et al : Irinotecan (CPT-ll) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86 : 446-449, 1994.
 
15) Kidani Y, et al : Antitumor activity of platinum (II) complexes of 1, 2-diamino-cyclohexane isomers. Gann 71 : 637-643, 1980.
PubMed
16) Extra JM, et al : Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25 : 299-293, 1990.
PubMed
17) Gamelin L, et al : Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions : a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10 (12 Pt 1) : 4055-4061, 2004.
 
18) Becouam Y, et al : Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16 : 2739-2744, 1998.
 
19) Machover D, et al : Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7 : 95-98, 1996.
PubMed
20) Douillard JY, et al : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer : a multicentre randomised trial. Lancet 355 : 1041-1047, 2000.
PubMed
21) Saltz LB, et al : Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 : 905-914, 2000.
 
22) Rothenberg ML, et al : Mortality associated with irinotecan plus bolus fiuorouracilAeucovorin : summary findings of an independent paneL J Clin Oncol 19 : 3801-, 2001,
 
23) Goto A, et al : Phase I川study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. Int J Clin Oncol 9 : 364-368, 2004.
 
24) Fujishima H, et al : Phase I study of CPT-lland bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer. Int J Clin Oncol 9 : 92-97, 2004.
 
25) Andre T, et al : CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35 : 1343-1347, 1999.
PubMed
26) 宇良敬ほか転移性大腸癌に対する持続静注型5FU/l-leucovorin+CPT-11併用療法 (FOLFIRI療法) の第1相試験 : 第42回日本癌治療学会抄録集. S20-2, 2004.
 
27) Andre T, et ai : Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17 : 3560-3568, 1999.
 
28) Rougier P, et al : Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure : arandomised, multicentre phase II study. Ann Oncol 13 : 1558-1567, 2002.
PubMed
29) Rothenberg ML, et al : Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin : interim results of a phase III trial. J Clin Oncol 21 : 2059-2069, 2003.
PubMed
30) Goldberg RM, et al : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 : 23-30, 2004.
PubMed
31) Maindrault-Goebel F, et al : Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35 : 1338-1342, 1999.
 
32) Maindrault-Goebel F, et al : High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37 : 1000-1005, 2001.
 
33) Douillard JY, et al : Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 : 3605-3616, 2002.
PubMed
34) Cammichael J, et al : Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 : 3617-3627, 2002.
PubMed
35) Shirao K, et al : Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer : joint United States and Japan study of UFT/LV. J Clin Oncol 22 : 3466-3474, 2004.
 
36) Van Cutsem E, et al : Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer : results of a large phase III study. J Clin Oncol 19 : 4097-4106, 2001.
 
37) Van Cutsem E, et al : Oral capecitabine vs intravenous 5-fluorouracil and leucovorin : integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90 : 1190-1197, 2004.
PubMed
38) Hoff PM, et al : Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer : results of a randomized phase III study. J Clin Oncol 19 : 2282-2292, 2001.
 
39) Shirao K, et al : Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100 : 2355-2361, 2004.
 
40) Cassidy J, et al : XELOX (capecitabine plus oxaliplatin) : active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22 : 2084-2091, 2004.
PubMed
41) Shields AF, et al : Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine : a phase II trial. Cancer 100 : 531-537, 2004.
PubMed
42) Bajetta E, et al : Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100 : 279-287, 2004.
PubMed
43) Ferrara N, et al : Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 : 391-400, 2004.
PubMed
44) Hurwitz H, et al : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 : 2335-2342, 2004.
PubMed
45) Giantonio BJ, et al : High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer ; Results from the Eastern Cooperative Oncology Group (ECOG) Study E3200. 2005-ASCO Annual Meeting Abstruct No. 2, 2005.
 
46) Ciardiello F, et al : Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5 : 909-916, 1999.
PubMed
47) Saltz LB, et al : Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 : 120, 2004.
 
48) Schrag D : The Price Tag on progress-Chemotherapy for colorectal cancer. N Engl J Med 351 : 317-319, 2004.
PubMed
49) Lewis JH, et al : Participation of patientg. 65 years of age or older in cancer clinical trials. J Clin Oncol 21 : 1383-1389, 2003.
PubMed
50) Folprecht G, et al : Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer : a pooled analysis of clinical trials. Ann Oncol l 5 : 1330-1338, 2004.
 
51) Chau I, et al : Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91 : 1453-1458, 2004.
PubMed
52) Grothey A, et al : Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, Irmotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 : 1209-1214, 2004.
PubMed
53) Maindrault-Goebel F, ct al : Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15 : 1210-1214, 2004.
 
54) J W Adlard : Assessment of multiple markers for association with response rate (RR) and failure-free survival (FFS) in patients with advanced colorectal cancer (CRC) treated with chemotherapy in the MRC CRO8 (FOCUS) randomized trial. 2004 ASCO Annual Meeting Abstract No : 9506, 2004.
 
P.262 掲載の参考文献
1) 日本肝癌研究会編 : 臨床・病理原発性肝癌取扱い規約, 第4版. 東京, 金原出版, 2001.
 
2) Yamada R, Sato M, Kawabata M, et al : Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148 : 397-401, 1983.
PubMed
3) Matsui O, Kadoya M, Yoshikawa J, et al : Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization. Radiology l 88 : 79-83, 1993.
 
4) Konno T, Maeda H, Iwai K, et al : Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma : A preliminary report. Eur J Cancer Clin Oncol 19 : 1053, 1983.
 
5) Takayasu K, Muramatsu Y, Maeda T, et al : Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system : analysis of factors affecting local recurrence and survival rates. AJR 176 : 681-688, 2001.
PubMed
6) 岡崎正敏, 東原秀行, 小金丸史隆, ほか : 肝細胞癌に対する肝動脈塞栓術-切除不能例を中心に. 臨放 36 : 529-534, 1991.
 
7) Ikeda K, Kumada H, Saitoh S, et al : Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the cox proportional hazard model. Cancer 68 : 2150-2154, 1991.
PubMed
8) Matsui O, Kodoya M, Yoshikawa J, et al : Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization. Radiology 188 : 79-83, 1993.
 
9) Nishimine K, Uchida H, Matsuo N, et al : Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma : follow-up CT and therapeutic results. Cancer Chemother Pharmacol 33 : 60-68, 1994.
 
10) Savastano S, Miotto D, Casarrubea G, et al : Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis : a multivariate analysis of prognostic factors. J Clin Gastroenterol 28 : 334-340, 1999.
PubMed
11) Okusaka T, Okada S, Ueno H, et al : ; Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology 62 : 228-233, 2002.
PubMed
12) O'Suilleabhain CB, Poon RT, Yong JL, et al : Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90 : 325-331, 2003.
PubMed
13) Ueno K, Miyazono N, Inoue H, et al : Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma : Evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 88 : 1574-1581, 2000.
PubMed
14) Ikeda M, Maeda S, Shibata J, et al : Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 66 : 24-31, 2004.
PubMed
15) Ono Y, Yoshimasu T, Ashikaga R, et al : Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23 : 564-568, 2000.
PubMed
16) Bruix J, Llovet JM, Castells A, et al : Transarterial embolization versus symptomatic treatment in patients with advanced hepatocelllular carcinoma : results of a randomized, controlled trial in a single institution. Hepatology 27 : 1578-1583, 1998.
 
17) Pelletier G, Ducreux M, Gay F, et al : Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization : a multicenter randomized trial. J Hepatol 29 : 129-134, 1998.
 
18) Llovet JM, Real MI, Montana X, et al : Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma : a randomized control triaL Lancet 359 : 1734-1739, 2002.
PubMed
19) Lo CM, Ngan H, Tso WK, et al : Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 : 1164-1171, 2002.
PubMed
20) Okusaka T, Okada S, Nakanishi T, et al : Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Investigational New Drugs 22 : 169-176, 2004.
PubMed
21) Toyoda H, Nakano S, Kumada T, et al : The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52 : 295-299, 1995.
PubMed
22) Urabe T, Kaneko S, Matsushita E, et al : Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55 : 39-47, 1998.
PubMed
23) Okuda K, Tanaka M, Shibata J, et al : Hepatic arteriai infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 6 : 587-591, 1999.
 
24) Chung YH, Song IH, Song BC, et al : Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88 : 1986-1991, 2000.
 
25) Sakon M, Nagano H, Nakamori S, et al : Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94 : 435-442, 2002.
 
26) Ando E, Tanaka M, Yamashita F, et al : Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis analysis of 48 cases. Cancer 295 : 588-595, 2002.
 
27) Yamasaki T, Kimura T, Kurokawa F, et al : Prognostic Factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 40 : 171-178, 2005.
 
28) Eguchi H, Nagano H, Yamamoto H, et al : Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6 : 2881-2890, 2000.
PubMed
29) Yamasaki T, Kurokawa F, Shirahashi H, et al : Novel arterial infusion chemotherapy using cisplatin, 5-Fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 23 : 7-17, 2002.
PubMed
30) Yamasaki T, Kurokawa F, Takami T, et al : Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study : Is a high dose of the biochemical modulator effective? Hepatol Res 27 : 36-44, 2003.
PubMed
31) 古江尚 : シスプラチン肝動注製剤-DDP-H-. 日本臨床 59 : 670-673, 2001.
Medical*Online
32) 上野秀樹, 奥坂拓志, 岡田周市 : 肝癌への化学療法は予後改善にどの程度寄与しているか? 臨床消化器内科 17 : 1361-1367, 2002.
 
33) Leung TW, Tang AM, Zee B, et al : Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94 : 421-427, 2002.
PubMed
34) 山崎隆弘, 木村輝昭, 高見太郎, ほか : 肝癌-進行肝癌に対する持続動注化学療法を中心に. 臨床と研究 80 : 1227-1233, 2003.
Medical*Online
35) Yang TS, Chang HK, Chen JS, et al : Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma : an analysis of 63 cases. J Gastroenterol 39 : 362-369, 2004.
 
36) Nagahama H, Okada S, Okusaka T, et al : Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol 27 : 321-324, 1997.
PubMed
37) Okada S, Okazaki N, Nose H, et al : Prognostic factors in patients with hepatocelluar carcinoma receiving systemic chemotherapy. Hepatology 16 : 112-117, 1992.
 
P.269 掲載の参考文献
1) 高橋豊, 山下要, 北方秀一, ほか : Tumor dormancy therapyに基づく新しい抗癌剤の投与量設定法. 医学のあゆみ 203 : 159-160, 2002.
Medical*Online
2) Onoue M, Terada T, Okuda M, et al : Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer. Int J Clin Oncol 19 : 174-178, 2004.
 
3) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 15 : 2403-2413, 1997.
 
4) Okada S, Ueno H, Okusaka T, et al : Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31 : 7-12, 2001.
PubMed
5) Grunewald R, Kantarjian H, Du M, et al : Gemcitabine in leukemia ; A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10 : 406-413, 1992.
PubMed
6) Tempero M, Plunke"W, Van Haperen VR, et al : Randomized Phase II Comparison of Dose-lntense Gemcitabine : Thirty-Minute lnfusion and Fixed Dose Rate lnfusion in Patients With Pancreatic Adenocarcinoma. J Clin Oncol Jul 28, 2003.
 
7) Ducreux M, Rougier P, Pignon JP, et al : A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13 : 1185-1191, 2002.
PubMed
8) Reni M, Cordio S, Passardi A, et al : Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA). ASCO : Abstract#4010, 2004.
 
9) Okada S, Okusaka T, Ueno H, et al : A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer. ASCO : Abstract #682, 2002.
 
10) Nakamura K, Yamaguchi T, Ishihara T, et al : A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma. ASCO : Abstract#4134, 2004.
 
11) Neoptolemos JP, Dunn JA, Stocken DD, et al : Ajuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial. Lancet 358 : 1565-1566, 2001.
 
12) Bloomston M, Zervos EE, Rosemurgy AS 2nd, et al : Matrix metalloproteinases and their role in pancreatic cancer : a review of preclinical studies and clinical trials. Ann Surg Oncol 9 : 668-674, 2002.
PubMed
13) Xiong HQ, Abbruzzese JL : Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 : 31-37, 2002.
PubMed
P.276 掲載の参考文献
1) Fisher B, ct a1 : Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 : 2672-2685, 1998.
 
P.281 掲載の参考文献
1) 斎田俊明ほか : 皮膚悪性腫瘍取扱い規約. pp 16-37, 東京, 金原出版, 2002.
 
2) Anderson C, et al : Oncology 9 : 1149-1158, 1995.
PubMed
3) Hill GJ, et al : Cancer 53 : 1299-1305, 1984.
PubMed
4) Crosby T, et al : Cochrane Database Syst Rev, 2003.
 
5) 石原和之 : 現代医療 19 : 783-785, 1987.
 
6) Yamamoto A, et al : Int J Immunotherapy 12 : 73-78, 1996.
 
7) 山本明史ほか : Skin Cancer 1 : 47-53, 1986.
 
8) 山崎直也ほか : 日皮会誌 105 : 1439-1444, 1995.
 
9) Del Prete SA, et al : Cancer Treat Rep 68 : 1403-1405, 1984.
PubMed
10) McClay EF, et al : Semin Oncol 23 : 744-753, 1996.
 
11) Chapman PB, et al : J Clin Oncol 17 : 2745-2751, 1999.
PubMed
12) 宇原久ほか : 日皮会誌 110 : 979-982, 2000.
 
13) 厚生労働省がん助成金, 山本班.
 
14) 山本明史 : 悪性黒色腫の診断・治療指針. pp108-117, 東京, 金原出版, 2001.
 
15) Khayat D, et al : J Clin Oncol 11 : 2173-2180, 1993.
PubMed
16) Richard JM, et al : J Clin Oncol 17 : 651-657, 1999.
 
17) Rosenberg SA, et al : JAMA 27 : 907-913, 1994.
 
18) Middleton MR, et al : J Clin Oncon 8 : 158-166, 2000.
 
19) Jacquillat C, et al : Cancer 63 : 1873-1878, 1990.
 
20) Kirkwood JM, et al : J Clin Oncol 14 : 7-17, 1996.
 
21) 藤沢康弘ほか : 日皮会誌 113 : 399-404, 2003.
 
22) Leyvraz S, et al : ASCO2002 : Abstract No. 1360.
 
23) Ikeda S, et al : Drug Exp Clin Res 12 : 247-255, 1986.
PubMed
24) Guthrie TH, et al : J Clin Oncol 8 : 342-346, 1990.
PubMed
25) 池田重雄ほか : Skin Cancer 8 : 503. 513, 1993.
 
26) 鈴木正ほか : 癌と化学療法 24 : 16-22, 1997.
Medical*Online
27) Oguchi S, et al : J Dermatol 29 : 33-37, 2002.
PubMed
28) Fata F, et al : Cancer 86 : 2034-2037, 1999.
PubMed
P.290 掲載の参考文献
1) Pui CH, Evans WE, Gilbert JR : Meeting report : Intemational Childhood ALL Work-shop : Memphis, TN, 3-4 December 1997. Leukemia 12 : 1313-1318, 1998.
 
2) Kersey JH : Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90 : 4243-4251, 1997.
PubMed
3) Hayashi Y : Molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol 37 : 368-380, 2000.
PubMed
4) Reiter A, Schrappe M, Ludwig W, et al : Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM-86. Blood 84 : 3122, 1994.
PubMed
5) Kamps WA, Bokkerink JP, Hahlen K, et al : Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy : results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 94 : 1226-1236, 1999.
 
6) Tsuchida M, Ikuta K, Hanada R, et al : Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981 1995, Leukemia 14 : 2295-2306, 2000.
 
7) Toyoda Y, Manabe A, Tsuchida M, et al : Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18 : 1508-1516, 2000.
PubMed
8) Ribeiro RC, Broniscer A, Rivera GK, et al : Philadelphia chromosome positive acute lymphoblastic leukemia in children : durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia 11 : 1493-1496, 1997.
PubMed
9) Schrappe M, Arico M, Harbott J, et al : Philadelphia chromosome-positive (Ph-) childhood acute lymphoblastic leukemia : good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92 : 2730-2741, 1998.
PubMed
10) Kong X-T, Ida K, Ichikawa H, et al : Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t (16 ; 21) (p11 ; q22) and identification of a novel transcript. Blood 90 : 1192-1199, 1997.
 
11) 月本一郎, 編 : 小児血液・腫瘍疾患治療プロトコール集. 東京, 医薬ジャーナル社, 2003.
 
12) Creutzig U, Ritter J, Schellong G : Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75 : 1932-1940, 1990.
PubMed
13) Woods WG, Kobrinsky N, Buckley JD, et al : Timed-sequential iduction therapy improves postremission outcome in acute myeloid leukemia : a report from the Children's Cancer Group. Blood 87 : 4979-4989, 1996.
 
14) Michel G, Leverger G, Leblane T, et al : Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A proepective study from the French Society of Pediatric Hematology and lmmunology (SHIP). Bone Marrow Transplant 17 : 191-196, 1995.
 
15) Ravindranath Y, Yeager AM, Chang MN, et al : Autologous bone marrow transplatation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334 : 1428-1434, 1996.
 
16) Kosaka Y, Koh K, Kinukawa N, et al : Infant acute lymphoblastic leukemia with MLL gene rearrangements : outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 104 : 3527-3534, 2004.
PubMed
17) Murphy SB, Fairclough DL, Hutchison RE, et al : Non-Hodgkin's lymphomas of childhood : an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 7 : 186-193, 1989.
 
18) Magrath I, Adde M, Shad A, et al : Adults and children with small non cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14 : 925-934, 1996.
PubMed
19) Hudson MM, Donaldson SS : Hodgkin's Disease (In Pizza PA, Poplack DG eds). Principles and practice of pediatric Oncology 3d ed. pp523-543, New york, Raven, 1997.
 
P.295 掲載の参考文献
1) Cortes EP, Holland JF, Glidwell O : Amputation and adriamycin in primary osteosarcomas ; A5-year report. Cancer Treat Rep 62 : 271-277, 1978.
 
2) Jaffe N, Frei E, Link M, et al : Adjuvant chemothrapy of osteogenic sarcoma ; 5-years experience. Cancer Treat Rep 62 : 259-264, 1978.
 
3) Ettinger IJ, Douglass HO, Higby DS, et al : Adjuvant adriamycin and cis-diamminedichloroplatinum (cisplatin) in primary osteosarcoma. Cancer 47 : 248-254, 1981.
 
4) Niederle N, Scheulen ME, Cremer M, et al : Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rep 10 : 129-135, 1983.
 
5) Miser JS, Kinsella TJ, Triche TJ, et al : Ifosfamide with mesna uroprotection and etoposide : An effective regimen in the treatment of recurrent sarcomas and other tumors in children and young adults. J Clin Oncol 5 : 1191-1198, 1987.
 
6) Edomonson JH, Green SJ, Ivins JC, et al : A controlled pilot study of high dose methotrexate as post-surgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2 : 152-156, 1984.
 
6) Rosen G, Caparros B, Huvos AG, et al : Preoperative chemotherapy for osteogenic sarcoma : Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49 : 1221-1230, 1982.
PubMed
7) Eilber F, Giuliano A, Eckardt J, et al : Adjuvant chemotherapy for osteosarcoma : A randomized prospective trial. J Clin Oncol 5 : 21-26, 1987.
 
8) Link MP, Groorin AM, Horowitz M, et al : Adjuvant chemotherapy of high grade osteosarcoma of the extremity : Update results of the multi-institutional osteosarcoma study. Clin Orthop 270 : 8-14, 1991.
 
9) Rosen G, Caparros B, Huvos AG, et al : Preoperative chemotherapy for osteogenic sarcoma : Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49 : 1221-1230, 1982.
PubMed
10) Meyer PA, Heller G, Healey J, et al : Chemotherapy for nonmetastatic sarcoma : The Memorial Slone Kettering experience. J Clin Oncol 10 : 5-15, 1992.
 
11) Fuchs N, Bielack SS, Epler D, et al : Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9 : 893-899, 1998.
 
12) Jaffe N, Paed D, Traggis D, et al : Improved outlook for Ewings sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38 : 1925-1930, 1976.
PubMed
13) Rosen G, Caparros B, Nirenberg A, et al : Ewing's sarcoma : ten-year experience with adjuvant chemotherapy. Cancer 47 : 2204-2213, 1981.
PubMed
14) Jurgens H, Exner U, Gadner H, et al : Multidisciplinary treatment of primary Ewings sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61 : 23-32, 1988.
 
15) Burgert EO Jr, Nesbit ME, Gamsey LA, et al : Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone : intergroup study IESS-II. J Clin Oncol 8 : 1514-1524, 1990.
 
16) Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al : Multimodal therapy for the management of primary, nonmetastatic Ewings sarcoma of bone : a long-term follow-up of the First Intergroup study. J Clin Oncol 8 : 1664-1674, 1990.
 
17) Advani SH, Rao DN, Dinshaw KA, et al : Adjuvant chemotherapy in Ewings sarcoma. J Surg Oncol 32 : 76-78, 1986.
PubMed
18) Ahrens S, Hoffmann C, Jabar S, et al : Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone : the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 32 : 186-195, 1999.
 
19) Wexler LH, DeLaney TF, Tsokos M, et al : Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 78 : 901-911, 1996.
PubMed
20) Meyer WH, Kun L, Marina N, et al : Ifosfamide plus etoposide in newly diagnosed Ewings sarcoma of bone. J Clin Oncol 10 : 1737-1742, 1992.
 
21) Bramwell VH, Steward WP, Nooij M, et al : Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone : A European Osteosarcoma Intergroup study. J Clin Oncol 17 : 3260-3269, 1999.
 
22) Ham SJ, Hoekstra HJ, van der Graaf WT, et al : The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. J Clin Oncol 14 : 490-496, 1996.
 
23) Capanna R, Bertoni F, Bacchini P, et al : Malignant fibrous histiocytoma of bone. The experience at the Rizzoli lnstitute : report of 90 cases. Cancer 54 : 177-187, 1984.
 
24) Eilber FR, Giuliano AE, Huth JF, et al : A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma. Am J Clin Oncol 11 : 39-45, 1988.
PubMed
25) Pinedo HM, Bramwell VH, Mouridsen HT, et al : Cyvadic in advanced soft tissue sarcoma : a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 53 : 1825-1832, 1984.
PubMed
26) Bramwell VH, Mouridsen HT, Santoro A, et al : Cyclophosphamide versus ifosfamide : final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23 : 311-321, 1987.
PubMed
27) Elias A, Ryan L, Sulkes A, et al : Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7 : 1208-1216, 1989.
PubMed
28) Antman K, Crowley J, Balcerzak SP, et al : An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 : 1276-1285, 1993.
PubMed
29) Tiemer JF : Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults : meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350 : 1647-1654, 1997.
 
30) Frustaci S, Gherlinzoni F, De Paoli A, et al : Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles : results of the Italian randomized cooperative trial. J Clin Oncol 19 : 1238-1247, 2001.
 
31) Holscher HC, Bloem JL, Vanel D, et al : Osteosarcoma : chemotherapy-induced changes at MR imaging. Radiology 182 : 839-844, 1992.
PubMed
32) Goorin AM, Schwartzentruber DJ, Devidas M, et al : Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma : Pediatric Oncology Group Study POG-8651. J Clin Oncol 21 : 1574-1580, 2003.
 
33) Picci P, Sangiorgi L, Rougraff BT, et al : Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence of osteosarcoma, J Clin Oncol 12 : 2699-2705, 1994.
PubMed
P.301 掲載の参考文献
1) 精巣腫瘍取扱い規約第2版. 金原出版, 1997.
 
2) 日本癌治療学会がん診療ガイドライン委員会 : 抗がん剤適正使用のガイドライン-泌尿器がん-. Int J Clin Oncol 9 : 21-33, 2004.
 
3) Jones RH, Vasey PA : Part I : testicular cancer--management of early disease. Lancet Oncol 4 : 730-737, 2003.
PubMed
4) Jones RH, Vasey PA : Part II : testicular cancer--management of advanced disease. Lancet Oncol 4 : 738-747, 2003.
PubMed
5) Chester JD, Hall GD, Forster M, et al : Systemic chemotherapy for patients with bladder cancer-current controversies and future directions. Cancer Treat Rev 30 : 343-358, 2004.
PubMed
P.308 掲載の参考文献
1) 小宮山慎一, ほか : わが教室における婦人科がんの化学療法. 産婦人科治療 83 : 349-354, 2001.
 
2) 玉田裕, ほか : 婦人科がん化学療法の将来を展望する. 臨床婦人科産科 58 : 1208-1211, 2004.
 
3) Sardi JE, et al : Long-term follow-up of the first randomized trial using neoadjyvant chemotherapy in stage 1b squamous carcinoma of the cervix : the final results. Gynecoloncol 67 : 61-69, 1997.
 
4) Chang TC, et al : Randomized trial of neoadjubant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 18 : 1740-1747, 2000.
PubMed
5) Benedetti-Panici P, et al : Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer : results from the Italian multicenter randomized study. J Clin Oncol 20 : 179-188, 2002.
PubMed
6) Napolitano U, et al : The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIb) : a long-term randomized trial. Eur J gynaecol Oncol 24 : 51-59, 2003.
PubMed
7) Whitney CW, et al : Randomized compartion of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes : a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 17 : 1339-1348, 1999.
 
8) Rose PG, et al : Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med 340 : 1144-1153, 1999.
 
9) Keys HM, et al : Cisplatin, radiation, and adjuvant hysterectomy compaired with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 340 : 1154-1161, 1999.
 
10) Moris M, et al : Pelvic radiation with concurrent chemotherapy compaired with pelvic and para-aortic radiatioin for high-risk cervical cancer. N Eng J Med 340 : 1137-1143, 1999.
 
11) 岩坂剛 : 子宮頸部腺がんに対する化学療法. 産婦人科治療 88 : 24-29, 2004.
 
12) 斉藤豪, ほか : 子宮頸部腺がんの術前化学療法に関する研究. 日本婦人科腫瘍学会誌 20 : 460, 2002.
 
13) Lisson A, et al : Cisplatin-, epirubicin-and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8 : 969-972, 1997.
 
14) Dimopoulos MA, et al : Paclitaxel and cisplatin inadvanced or recurrent : carcinoma of the endometrium : long-term results of a phase II multicenter study. Gynecol Oncol 78 : 52-57, 2000.
PubMed
15) Fleming GF, et al : Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus paclitaxel (TAX) plus granulocyte colony-stimulating factor (G-CSF) in patients with advanced or recurrent endometrial cancer : a report on Gynecologic Oncology Group (GOG) ProtocoL Proc Am Soc Clin Oncol l 9 : 379a (Abstr 1498), 2000.
 
16) 進伸幸, ほか : 子宮内膜がんに対するホルモン療法. がんと化学療法 28 : 934-945, 2001.
 
17) 野澤志朗 : 婦人科学. 日本医事新報 4068 : 27-32, 2002.
Medical*Online
18) McGuire WP, et al : Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 334 : 1-6, 1996.
 
19) Piccart MJ, et al : Randomized intergroup trial of cisplatn- paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year results. J Natl Cancer Inst 92 : 699-708, 2000.
 
20) Ozols RF, et al : Randamized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III ovarian cancer : a Gynecoiogic Oncology Group Trial (GOG158). Proc Am Soc Clin Oncol 18 : 356a, 1999.
 
P.314 掲載の参考文献
1) 佃守 : 主要臓器進行癌治療, 頭頸部癌. 癌と化学療法 25 : 1657-1664, 1998.
 
2) Vokes E E, Athanasiadis I : Chemotherapy for squamous cell carcinoma of head and neck : The future is now. Annals Oncology 7 : 15-29, 1996.
 
3) Pignon J P, Bourhis J, Domenge C, et al : ; Chemotherapy added to locoregionanreatment for head and neck squamous cell carcinoma : three meta-analyses of updated individual data. Lancet 355 : 949-955, 2000.
PubMed
4) Browman G P, Hodson D I, Mackenzie R J, et al : Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer : a systematic review of the published literature with subgroup analysis. Head Neck 23 : 579-589, 2001.
PubMed
5) The Department of Veterans Affairs Laryngeal Cancer Study Group : Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngea1 cancer. N Engl J Med 324 : 1685-1690, 1991.
 
6) Lefebvre J L, Chevalier D, Luboinski B, et al : Larynx preservation in pyriform sinus cancer. preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 : 890-899, 1999.
 
7) Haddad R, Colevas A D, Tishler R, et al : Docetaxel, cisplatin, and 5-fiuorouracil-based induction chemotherapy in patients with locally advanced g. quamous cell carcinoma of the head and neck. The Dana Farber Cancer Institute Experience. Cancer 97 : 412-418, 2003.
 
8) Tsukuda M, Mikami Y, Tanigaki Y, et al : Phase I trial of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil for patients with locally advanced head and neck squamous cell carcinoma of the head and neck. Int. J Clin Oncol 9 : 161-166, 2004.
PubMed
9) Vermorken J B, Remenar E, Van Herpen C, et al : Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) : aphase III trial of the EORTC head and neck cancer group (EORTC24971). Proc Am Soc Clin Oncol 23 : 17 (Absta. 5508), 2004.
 
10) Monnerat C, Faivre S, Temam S, et al : End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Annals Oncol 13 : 995-1006, 2002.
 
11) Pignon J P, Syz N, Posner M, et al : Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anti-Cancer Drugs 15 : 331-340, 2004.
PubMed
12) Cooper J S, Pajak T F, Forastiere A A, et al : Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 350 : 1937-1944, 2004.
PubMed
13) Bemier J, Domenge C, Ozsahin M, et al : Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 : 1945-1952, 2004.
PubMed
14) Katori M, Tsukuda M, Mochimatu I, et al : Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90 : 348-352, 2004.
 
P.320 掲載の参考文献
1) 脳腫瘍全国統計委員会 : 脳腫瘍取り扱い規約 ; 臨床と病理アトラス. 日本病理学会 (編). pp 1-66, 東京, 金原出版, 2002.
 
2) Brem H, Ewend MG, Piantadosi S, et al : The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas : phase I trial. J Neuroonco126 : 111-123, 1995.
PubMed
3) Stewart LA : Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-1018, 2002.
PubMed
4) Takakura K, Abe H, Tanaka R, et al : Effects of ACNU and radiotherapy on malignant gliomas. J Neurosurg 64 : 53-57, 1986.
PubMed
5) Wakabayashi T, Hatano N, Kajita Y, et al : Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 49 : 57-62, 2000.
PubMed
6) Kornblith PL : The role of cytotoxic chemotherapy in the treatment of malignant brain tumors. Surg Neuro 144 : 551-552, 1995.
 
7) Yung WK, Prados MD, Yaya-Tur R, et al : Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 : 2762-2771, 1999.
PubMed
8) Prados MD, Scott C, Curran WJ Jr, et al : Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma : A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17 : 3389-3395, 1999.
PubMed
9) Medical Research Council Brain Tumor Working Party : Randomized trial of procarbazine, Iomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma : a Medical Research Council trial. J Clin Oncol 19 : 509-518, 2001.
 
10) Caimcross JG, Macdonald DR : Successful chemotherapy for recurrent malignant oligo-dendroglioma. Ann Neurol 23 : 360-364, 1988.
 
11) Prados MD, Scott C, Curran WJ Jr, et al : Procarbazine, lomustine, and vincri stine (PCV) chemotherapy for anaplastic astrocytoma : A retrospective review of radiation therapy oncology gr卯p protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17 : 3389-3395, 1999.
 
12) Jeremic B, Shibamoto Y, Gruijicic D, et al : Combined treatment modality for anaplastic oligodendroglioma : a phase II study. J Neurooncol 43 : 179-185, 1999.
PubMed
13) Sawamura Y, Ikeda J, Ishii N, et al : Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor-results of a pilot study. Neurol Med Chir (Tokyo) 36 : 632-638, 1996.
PubMed
14) Chang CH, Housepian EM, Herbert C Jr : An operative staging system and a mega-voltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93 : 1351-1359, 1969.
 
15) Einhom LH, Donohue J : Cis-diammine-dichloroplatinum, vinblastine, and bleo-mycin combination chemotherapy in dis-seminated testicular cancer. Ann Intern Med 87 : 293-298, 1977.
 
16) Hiraga S, Arita N, Ohnishi T, et al : Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91 : 221-230, 1999.
PubMed
17) DeAngelis LM, Gustin PH, Leibel SA, et al (eds) : Primary central nervous system lymphom and other hemopoietic tumors. Intracranial Tumors, Diagnosis and Treatment. pp320-339, Martin Dunitz (London), 2002.
 
P.325 掲載の参考文献
1) Sahn SA : State of the art. The pleura. Am Rev Respir Dis 138 : 184-234, 1988.
PubMed
2) Villena V, Lopez Encuentra A, Echave-Sustaeta J, et al : Prospective study of 1,000 consecutive patients with pleural effusion and characteristic of the patients. Arch Bronconeumol 38 : 21-26, 2002.
 
3) Leuallen EC, Carr DT : Pleural effusion ; a statistical study of 436 patients. N Engl J Med 252 : 79, 1955.
PubMed
4) Salyer WR, et al : Efficacy of pleural needle biopsy and pleural fiuid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 67 : 536-539, 1975.
 
5) Winkelmann M, et al : Blind pleural biopsy in combination with cytology of pleural effusion. Acta Cytol 25 : 373-376, 1981.
PubMed
6) American Thoracic Society : Management of malignant pleural effusion. Am J Respir Crit Med 162 : 1987-2001, 2000.
 
7) Canto A, Rivas J, Saumench J, et al : Points to consider when choosing a biopsy method in cases of pleurisy of unknown origin. Chest 84 : 176-179, 1983.
PubMed
8) 一瀬幸人 : 癌性胸膜炎の冶療. Annual Review呼吸器. pp230-236, 東京, 中外医学社, 1996.
 
9) Yoshida K, et al : Randomized phase II of three in tratrapleural therapy regimens in non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) : Japan clinical oncology group study (JCOG9515). Proc Am Soc Clin Oncol 20 : 339a, 2001 (Abstr).
 
10) Belani CP, et al : Treating malignant pleural effusions cost consciously. Chest 113 : 78S-85S, 1998.
PubMed
11) Rusch VW, Figlin R, Godwin D, et al : Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions : A Lung Cancer Study Group Trial. J Clin Oncol 9 : 313-319, 1991.
 
12) Tohda Y, Iwanaga T, Takeda M, et al : Intrapleural administration of cisplatin and etoposide to treatment malignant pleural effusion in patients with non-small lung cancer. Chemotherapy 45 : 197-204, 1999.
 
13) Moores DWO, Ruckdeschel JC : Pleural effusions in patients with malignancy. Thoracic oncology (ed by Roth JA, et al), Philadelphia, WB Saunder, 1995.
 
14) Hausheer FH, Yarbro JW : Diagnosisand treatment of malignant pleural effusion. Semi Oncol 12 : 54, 1985.
 
15) Senger DR, Van de Water L, Brown LF, et al : Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metatasis Rev 12 : 303-324, 1993.
 
16) 兵頭一之介 : 難治疾患の緩和医療 ; 腹水. カレントテラピー 16 : 49-53, 1998.
 
17) 山口俊晴, 高橋俊雄, 沢井清司, ほか : 癌性腹膜炎・癌性イレウスの治療. 日外会誌 100 : 211-215, 1999.
 
18) Torresini RJ, Prolla JC, Diehl ARS, et al : Combined carcinoembryonic antigen and cytopathologic examination in ascites. Acta Cytol 44 : 778-782, 2000.
 
19) SmithEM, Jayson GC : The current and future management of malignant ascites. Clin Oncol 15 : 59-72, 2003.
PubMed
20) Tahara M, Ohtsu A, Boku N, et al : Sequential methotrexate and 5-fliorouracil therapy for gastric cancer patients with peritoneal dissemination : a retrospective study. Gastric Cancer 4 : 212-218, 2001.
 

IX. 抗がん剤の適正使用ガイドライン

P.331 掲載の参考文献
1) 有吉寛 : 抗がん剤適正使用ガイドライン (総論). 癌と化学療法. 29 : 970-977, 2002.
Medical*Online
2) Sackett DL, Haynes RB, Guyatt GH, et al : Clinical epidemiology, a basic science for clinical medicine (second Ed.). Boston Little Brown and Comapany, 1991.
 
3) 名郷直樹 : EBM実践ワークブック-よりよい治療をめざして-東京, 南江堂, 1999.
 
4) Rapp PA, Pater JL, William A, et al : Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer + Report of a Canadian multicentre randomized trial. J Clin Oncol 6 : 633-641, 1988.
 
5) Woods RL, Williams CJ, Levi J, et aI : A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61 : 608-611, 1990.
 
6) Cellerino R, Tummarello D, Guidi F, et al : A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 9 : 1453-1461, 1991.
PubMed
7) Cartei G, Cartei F, Cantone A, et al : Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive carg versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 85 : 794-800, 1993.
 
8) Souquet PJ, Chauvin F, Boissel JP, et al : Polychemotherapy in advanced non small cell lung cancer : a meta-analysis. Lancet 342 : 19-21, 1993.
 
9) Non-small Cell Lung Cancer Collaborative Group : Chemotherapy in non-small cell lung cancer : a metaanalysis using update data on individual patients from 52 randomized clinical trials. B M J 311 : 899-909, 1995.
 
P.336 掲載の参考文献
1) 食道癌治療ガイドライン (食道疾患研究会編). 金原出版, p. 32, 2002
 
2) 西尾正道, 森田皓三, 山田哲也, 他34名 : 食道がんMO症例の放射線治療成績の全国集計. 日癌治 27 : 912-924, 1992
 
3) Okawa T, Kita M, Tanaka M, et al : Results of radiotherapy for imperable loccally advanced esophageal cancer. Int J Radiation Oncology Biol. Phys. 17 : 49-54, 1989
 
4) Al-Sarraf M, Martz K, Herskovic A, et al : Progress report of combined chemoradiotherapy versus radiotherapy a l one in patients with esophageal cancer : An intergroup study. J Clin Oncol 15 : 277-284, 1997
 
5) Coia LR, Minsky BD, Berkey BA, et al : Outcomes of patients receiving radiation for cancer of the esophagus : results of the 1992-1994 pattern of care study. J Clin Oncol 18 : 455-462, 2000
PubMed
6) Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, et al : Improvement in the results of surgical treatment of advanced squanous esophageal carcinoma during 15 consecutive years. Ann Surg, 232 : 225-232, 2000
 
7) The Japanese Society fo1 Esophageal Deseases : Comprehensive registry of esophageal cancer in Japan (1998, 1999) & Long-term results of esophagectomy in Japan (1988-1997) 3rd edition p. 99-109, 2002
 
8) Ishida K, Iizuka T, Ando N, et al : Phase II Study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus : Nine Japanese Institute Trail. Jpn J Clin Oncol 26 : 310-315, 1996
 
9) Ishida K, Ando N, Yamamoto S, et al : Phase II Study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus : aJapan Esophageal Oncology Group (JEOG) /Japan Clinical Oncology Group Trial (JCOG9516) Jpn J Clin Oncol 34 : 615-619, 2004
 
10) Ohtsu a, Boku N, Muro K, et al : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17 : 2915-2921, 1999
PubMed
11) Hironaka S, Ohtsu A, Boku N, et al : Nonrandomaized comparison between definiteve chemoradiotherapy and radical surgery in patients with T2-3 NanyM0 squamous cell carcinoma of the esophagus. lnt J Radiat Oncol Biol Phys 57 : 425-433, 2003
 
12) 安藤暢敏, 小澤壮治, 北側雄光, ほか : T4食道癌に対する化学・放射線療法後の根治手術. 日外会市 98 : 2059-2064, 1999
 
13) Nishimski T, Tanaka O, Ando N, et al : Evaluation of the accuracy of preoperative staging in thoracic esophagial cancer. Ann Thorac Surg 68 : 2059-2064, 1999
 
14) Kato H, Udagawa O, Ando N, et al for the Japan Clinical Oncology Group : A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma : Japan Clinical Oncology Group study (JCOG9708). Proc Am Soc Clin Oncol 22 : 286, 2003
 
15) Igaki H, Kato H, Tachimori Y, et al : Clonicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinoma of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 20 : 1089-1094, 2000
 
P.340 掲載の参考文献
1) Ebara M, Ohto M, Sugiura N, et al : Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma, Study of 95 patients. J Gastroenterol Hepatol. Nov-Dec 5 : 616-626, 1990.
 
2) Shiina S, Tagawa K, Niwa Y, et al : Percutaneous ethanol injection therapy for hepatocellular carcinoma : results in 146 patients. AJR Am J Roentgenol. May 160 : 1023-1028, 1993.
PubMed
3) Seki T, Wakabayashi M, Nakagawa T, et al : Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74 : 817-825, 1994.
PubMed
4) Livraghi T, Goldberg SN, Lazzaroni S, et al : Small hepatocellular carcinoma : treatment with radio-frequency ablation versus ethanol injection. Radiology Mar 210 : 655-661, 1999.
PubMed
5) 菅原寧彦, 幕内雅敏 : 肝細胞癌における肝移植の適応と成績. 外科 (0016-593X) 64巻11号. pp 1304-1306, 2002.
 
6) 椎名秀一朗, 寺谷卓馬, 佐藤新平, ほか : 肝細胞癌に対する経皮的ラジオ波焼灼術後の再発と予後について. 第39回日本肝癌研究会抄録集. pp125.
 
7) 第14回全国原発性肝癌追跡調査報告. pp75.
 
8) 寺谷卓馬, 椎名秀一朗, 小俣政男 : JIS Score及びCLIP Score別に見たラジオ波焼灼療法の予後. Acta Hepatologica Japonica 45 (Supple 2) : A353, 2004.
 
9) 椎名秀一朗, 石川 隆, 小俣政男 : 経皮的ラジオ波焼灼療法 (RFA) による肝腫瘍の治療. Acta Hepatologica Japonica 45 (Supple 2) : A392, 2004.
 
10) Mazzaferro V, Regalia E, Doci R, et al : Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 : 693-699, 1996.
PubMed
11) 日本肝移植研究会 : 肝移植症例登録報告.
 
12) Shiratori Y, Imazeki F, Moriyama M, et al : Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 : 517-524, 2000.
PubMed
13) Yoshida H, Shiratori Y, Moriyama M, et al : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 : 174-181, 1999.
 
14) Shiratori Y, Shiina S, Teratani T, et al : Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 : 299-306, 2003.
PubMed
15) 寺谷卓馬, 椎名秀一朗, 小俣政男 : 高齢化した肝癌におけるラジオ波焼灼療法の意義. Acta Hepatologica Japonica 45 (supple 2) : A411, 2004.
 
16) 小池幸宏, 本田普久, 瀬戸元子, ほか : 高齢者肝癌に対するラジオ波焼灼療法. 日本成人病学会会誌 29 : 64, 2003.
 
P.343 掲載の参考文献
1) Early Breast Cancer Trialists-Collaborative Group : Polychemotherapy for early breast cancer : An overview of the randomized trials. Lancet 352 : 930-942, 1998.
 
2) By the French Adjuvant Study Group : Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors : 5-Year Follow-Up Results of French A (ijuvant Study Group 05 Randomized Trial. J Clin Oncol 19 : 602-611, 2001.
 
3) Henderson C l, et al : Improved Disease-Free And Overall Survival From The Addition of Sequential Paclitaxel But Not From The Escalation of Adriamycin Dose Level in The Adjuvant Chemotherapy of Patients With Node-Positive Primary Breast Cancer. Proc Am Soc Clin Oncol 17 : 101a (abstr390A), 1998.
 
4) Antman KH, Rowlings PA, Vaugham WP, et al : High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J clin Oncol 15 : 1870, 1997.
 
5) Hortobagyi GN, Buzdar AU, Theriault RL, et al : Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma J Natl Cancer Inst 92 : 225-233, 2000.
PubMed
6) Rodenhuis S, Richel DJ, van der Wall E, et al : Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352 : 515-521, 1998.
PubMed
7) Bergh J Wiklund T, Erikstein B, et al : Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as a (ljuvant treatment for high-risk breast cancer : A randomized trail-Scandinavian Breast Group 9401 study. Lancet 356 : 1384-1391, 2000.
 
8) Rodenhuis S, Bontenbal M, Beex LV, et al : high-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 : 7-16, 2003.
PubMed
9) Tallman MS, Gray R, Robert NJ, et al : Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349 : 17-26, 2003.
PubMed
10) Tokuda Y, Tajima T, Narabayashi M, et al : Randomized phase III study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer : Japan Clinical Oncology Group (JCOG9208). Proc Am Soc Clin Oncol 20 : 38a, 2001 (abstr148).
 
11) 徳田裕, 鈴木育宏, 齋藤雄紀, ほか : ランダム化比較試験によって乳がん大量化学療法の意義は否定されたのか?. 血液・腫瘍科47巻, 4号 : 353-360, 2003.
 
12) 徳田裕 : 乳がん治療における大量化学療法の位置づけ. Key Trial 7巻 : 5-11, 2001.
 
13) http://www.heratrial.com
 
14) Chemotherapy for breast cancer, Treatment Guidelines from The Medical Letter 2005 Jan guideline on role of taxanes in neoadjuvant chemotherapy http://www.dynamicmedicaLcom/dynamed.nsf
 
15) Cochrane Library 2003 Issue I : CD003142
PubMed
16) J Bergh, T Wiklund, B Erikstein, et al : Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomized trial. Scandinavian Breast Group 9401 study. Lancet 356 : 1384-1391, 2000.
 
17) A R Zander, N Kroger, C Schmoor, et al : High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes : First Results of a Randomized Trial. Journal of Clinical Oncology 22 : 2273-2283, 2004.
PubMed
18) Gabriel N : Hortobagyi : What Is Role of High-Dose Chemotherapy in the Era of Targeted Therapies? Journal of Clinical Oncology 22 : 2263-2266, 2004.
PubMed
P.349 掲載の参考文献
1) 中島聰偲, 太田恵一朗, 石原省 : Meta-analysisによる胃癌術後補助化学療法の再評価. 癌と化学療法 21 : 1800-1805, 1994.
 
2) Macdonald JS, Smalley SR, Benedetti J, et al : Chemoraidotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl Med 345 : 725-730, 2001.
 
3) Cuschieri A, Weeden S, Fielding J, et al : Patient survival after D1 and D2 resections for gastric cancer : Long-term results of the MRC randomized surgical tral. Surgical Co-operative Group. Br J Cancer 79 : 1522-1530, 1999.
 
4) Nakajima T, Nashimoto A, Kitamura M, et al : Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer : A randomized trial. Gastric Cancer Surgical Study Group. Lancet 354 : 273-277, 1999.
 
5) 坂本純一, 浜田知久馬, 加藤潤二, ほか : メタアナリシスを中心とした大腸癌補助療法の評価. 日本大腸肛門病誌 53 : 1008-1017.
 
6) Moertel CG, Fleming TR, Macdonald JS, et al : Levamisole and fluorouracil for adjuvant therapy of・resected colon carcinoma. N Engl J Med 322 : 352-358, 1990.
 
7) Wolmark N, Rockette H, Mamounas E, et al : Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes, B and C carcinoma of the colon : Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 : 3553-3559, 1999.
 
8) Haller DG, Catalano PJ, Macdonald JS, et al : Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer : five-year final report of INT-0089. Proc Am Soc Clin Oncol 17 : 256a, 1998 (abstr. 982).
 
9) Mamounas E, Wieand S, Wolmark N, et al : Comparative efficacy of adjuvant chemotherapy in patients with Dukes' Bversus Dukes' Ccolon cancer : Results from four National Surgical A (ljuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 : 1349-1355, 1999.
 
10) Efficacy of adjuvant fluorouracil and folic acid in colon cancer. Intemational Multicentre Pooled Analysis ot' Colon Cancer Trials (IMPACT) investigators. Lancet 345 : 939-944, 1995.
 
11) O'Connell MJ, Laurie JA, Kahn M, et al : Prospectively randomized trial of postoperative a (ijuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16 : 295-300, 1998.
PubMed
12) Kusunoki M, Yanagi H, Noda M, et al : The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep 6 : 547-552, 1999.
PubMed
13) Kusunoki M, Yanagi H, Kotera H, et al : Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol 13 : 653-657, 1998.
PubMed
14) Yoshikawa R, Kusunoki M, Yanagi H, et al : Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells : a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61 : 1029-1037, 2001.
 
15) Yanagi H, et al : Randomized clinical trial of pharmacokinetic modulating chemotherapy (PMC) in combination with continuous 5-FU infusion plus oral UFT for adjuvant chemotherapy after curative resection for Dukes' C colorectal cancer patients. Proc Am Soc Clin Oncol 22 : 293, 2003 (abstr1175).
 
16) Malet-Martino M, Martino R : Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1) : a review. Oncologist 7 : 288-323, 2002.
PubMed
30) Wolmark N, Wieand S, Lembersky L, et al : A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon : Results of NSABP Protocol C-06. Proc Am Soc Clin Oncol 22 : 2004 (abstr. 3508).
 
P.355 掲載の参考文献
1) Mountain CF : Revisions in the international system for staging lung cancer. Chest 111 : 1710-1717, 1997.
PubMed
2) Roth JA, Fossella F, Komaki R, et al : A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 : 673-680, 1994.
PubMed
3) Roth JA, Atkinson EN, Fossella F, et al : Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21 : 1-6, 1998.
 
4) Rosell R, Gomez-Codina J, Camps C, et al : A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 : 153-158, 1994.
PubMed
5) Rosell R, Gomez-Codina J, Camps C, et al : Preresectional chemotherapy in stage IIIA non-small-cell lung cancer : a 7-year assessment of a randomized controlled trial. Lung Cancer 47 : 7-14, 1999.
 
6) Depierre A, Milleron B, Moro-Sibilot D, et al : Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage 1 (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 : 247-253, 2001.
 
7) Pass HI, Pogrebniak HW, Steinberg SM, et al : Randomized trial of neoadjuvant therapy for lung cancer : interim analysis. Ann Thorac Surg 53 : 992-998, 1992.
PubMed
8) Nagai K, Tsuchiya R, Mori T, et al : A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg l 25 : 254-260, 2003.
 
9) PistersKM, Ginsberg RJ, Giroux DJ, et al : Induction chemotherapy before surgery for early-stage lung cancer : a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119 : 429-439, 2000.
PubMed
10) Albain KS, Scott CB, Rusoh VR, et al : Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC) : initial results from Intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 22 : 621, 2003.
 
11) Niiranen A, Niitamo-Korhonen S, Kouri A, et al : Adjuvant chemotherapy after radical surgery for non-small-ce1川ung cancer : a randomized study. J Clin Oncol 10 : 1927-1932, 1992.
 
12) Feld R, Rubinstein L, Thomas PA : Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage 1 non-small-cell lung cancer : The Lung Cancer Study Group. J Natl Cancer Inst 85 : 299-306, 1993.
 
13) Ohta M, Tsuchiya R, Shimoyama M, et al : Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer : results of a randomized prospective study. J Thorac Cardiovasc Surg 106 : 703-708, 1993.
PubMed
14) Wada H, Hitomi・S, Teramatsu・T, et al : Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14 : 1048-1054, 1996.
 
15) Non-small cell lung cancer collaborative group : Chemotherapy in non-small cell lung cancer : a meta-analysis using updated data on invididual patients from 52 randomised clinical trials. BMJ 311 : 899-909, 1995.
 
16) Keller SM, Adak S, Wagner H, et al : A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 343 : 1217-1222, 2000.
PubMed
17) Scagliotti GV, Fossati R, Torri V, et al : Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95 : 1453-1461, 2003.
PubMed
18) Waller D, Fairlamb DJ, Gower N, et al : The Big Lung Trial (BLT) : Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC) lpreliminary results in the surgical setteing. Proc Am Soc Clin Oncol 22 : 632, 2003.
 
19) The International A (ljuvant Lung Cancer Trial Collaborative Group : Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 : 351-360, 2004.
 
20) Winton TL, Livingston R, Johnson D, et al : A prospective randomised trial of adjuvant vinorelbine (VNB) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC). Intergroup JBR. 10. J Clin Oncol 22 : 621, 2004 (2004 ASCO Annual Meeting Proceedings).
 
21) Strauss GM, Herndon J, Maddaus MA, et al : Randomized clinical trial of adj uvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC) : report of Cancer and Leukemia Group B (CALGB) Protocol 9633, J Clin Oncol 22 : 621, 2004 (2004 ASCO Annual Meeting Proceedings).
 
22) Kato H, Ichinose Y, Ohta M, et al : A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 : 1713-1721, 2004.
PubMed
23) Hamada C, Ohta M, Wada H, et al : Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 22 : 617, 2004 (2004 ASCO Annual Meeting Proceedings)
 

書評

最近チェックした商品履歴

Loading...